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Abstract 
Intravenous immunoglobulin (IVIG) is a common treatment for the neurological 
autoimmune diseases multiple sclerosis, multifocal motor neuropathy, myasthenia gravis, 
and chronic inflammatory demyelinating polyneuropathy. However, there is scant 
literature regarding the psychological effects of this treatment on quality of life (QOL). 
Using illness intrusiveness theory and personal control theory, this correlational, cross-
sectional study examined the relationship between the IVIG treatment experience and 
QOL in neurological autoimmune patients. Surveys were employed to collect data from 
79 patients at a neurological infusion center in Phoenix, AZ. Quantitative analyses 
included correlation, multiple regression, and mediation analyses to determine whether 
(a) IVIG treatment experience predicted QOL measured by 10 Neuro-QOL scales, (b) 
illness intrusiveness mediated the relationship between IVIG treatment experience and 
QOL, and (c) personal control mediated the relationship between illness intrusiveness and 
QOL. IVIG treatment experience predicted QOL in 1 Neuro-QOL subscale; illness 
intrusiveness mediated 9 of the Neuro-QOL subscales using bias-corrected bootstrapping 
for statistical significance; and personal control did not mediate the relationship between 
illness intrusiveness and QOL. These results may affect social change by increasing the 
understanding of physicians, nurses, and patients regarding the psychosocial impact of 
IVIG treatment. Results from the study may provide insight for interventions to assist 
patients in adjusting to this form of treatment. 
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Chapter 1: Introduction to the Study  
Introduction 
Autoimmune neurological disorders such as multiple sclerosis (MS), multifocal 
motor neuropathy (MMN), myasthenia gravis (MG), and chronic inflammatory 
demyelinating polyradiculoneuropathy (CIDP) affect millions of people in the United 
States. The National Institutes of Health (NIH), part of the United States Department of 
Health and Human Services (USDHHS), considers only the diseases that have sound 
epidemiology studies in their 23.5 million estimated autoimmune disease statistics (NIH, 
2005). These autoimmune diseases often physically disable people through loss of 
function, mobility, and weakness, while decreasing the individual's quality of life (QOL) 
through psychological factors such as depression, anxiety, frustration, inconvenience, lost 
interest in surroundings, fatigue, and intrusion into daily life activities (Padua, Sabatelli, 
Evoli, Pazzaglia, & Tonali, 2005).  
Neurological autoimmune diseases affect the central or peripheral nervous system 
(Appenzeller, Shoenfeld, & de Carvalho, 2012). Included in the neurological autoimmune 
disease family are the four diseases which were examined in this study. MS is a disease 
resulting in demyelination of the central nervous system often producing lasting 
neurological impairment (Padua et al., 2005). MMN is an uncommon, progressive 
demyelinating disorder producing distal and upper limb weakness, conduction block in 
the motor nerves, difficulty in walking, and poor dexterity and affects 1–2 people in 
100,000 (Nobile-Orazio, Cappellari, & Priori,. 2005). MG affects an estimated 14–20 
people per 100,000 (Myasthenia Gravis Foundation of America, 2012), is often 
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progressive with long-term disability (Leonardi et al., 2010), and is characterized by 
weakness in muscles and extreme fatigue (Maggi & Mantegazza, 2011). CIPD is a 
progressive disease often displaying weakened reflexes and sensory loss (Patel, 
Bhanushali, & Muley, 2010) along with diminished muscle strength in both upper and 
lower extremities often affecting balance and mobility (Hughes, 2009; Westblad, 
Forsberg, & Press, 2009) with tendon reflexes often reduced (Hughes, 2010). More 
detailed descriptions of these four diseases are provided in Chapter 2.  
Although there are several treatments used in autoimmune disease, a select 
treatment for the four diseases examined in this study was intravenous immunoglobulin 
(IVIG; Dalakas, 2004) which is immunoglobulin obtained from healthy individuals (Bick 
et al., 2013). It was important to examine the effect of IVIG treatment experience since 
the impact of treatment may contribute to an intrusion or interruption of lifestyle and 
activities of enjoyment for patients while at the same time benefiting the physical 
symptoms of the disease. This disruption to life activities and patient interests is defined 
as illness intrusiveness and is hypothesized to compromise QOL (Devins, 2010; 
Poochikian-Sarkissian, Sidani, Wennberg, & Devins, 2008a). Illness intrusiveness was a 
mediator variable between the IVIG experience and QOL in this study.  
QOL was the outcome variable in this study. While considerable research exists 
concerning the compromising effects of chronic neurological disease symptoms on QOL, 
there is limited research on the influence of the potential intrusion of treatment on QOL 
for these diseases. Examining the treatment experience and its effect on QOL may 
contribute to current research in understanding patient experiences with regard to IVIG. 
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The current study examined the relationships between this particular treatment (IVIG), 
the predictor variable, and QOL in a population of MS, MMN, MG, and CIDP patients. 
Background 
Although the NIH considers only the diseases which have sound epidemiological 
studies in their prevalence estimates of 23.5 million autoimmune disease,  the American 
Autoimmune Related Diseases Association (AARDA) and the National Coalition of 
Autoimmune Patient Groups (NCAPG)  report researchers have identified 80 to 100 
chronic potentially life threatening diseases making the estimation closer to 50 million 
individuals in the United States affected by autoimmunity diseases (AARDA & NCAPG, 
2011; USDHHS, NIH, 2005). Living with one of these autoimmune diseases is 
challenging, from coping with disease symptoms to the consequences associated with the 
prescribed treatment. Autoimmune diseases treated with IVIG include (but are not limited 
to) Kawasaki disease, idiopathic thrombocytopenic purpura (ITP), guillain-barré, 
dermatomositis, stiff person syndrome, and the four diseases focused on in this study. 
A common treatment for the four autoimmune diseases is IVIG. IVIG is 
developed from the plasma of 1,000 to 10,000 individuals forming a “unit” of the purified 
blood product and is used for treatment in a variety of neurological diseases (Phoenix 
Neurological Associates [PNA], 2015). IVIG consists of antibodies which serve to 
impede the attack on the individual’s immune system (Dalakas, 2004). 
Numerous research articles have been published regarding the efficacy of IVIG 
with autoimmune neurological disorders. For example, IVIG is thought to delay 
progression in some forms of MS and offers safe and efficacious treatment in relapsing-
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remitting MS (Katz, Kishner, Magalashvili, Shoenfeld, & Achiron, 2006; Pöhlau et al., 
2007). Moreover, IVIG mollifies exacerbations in moderate to severe MG patients 
(Gajdos & Chevret, 2008; Zinman & Bril, 2008), and improves disease specific QOL in 
MG patients (Bril, Barnett-Tapia, Barth, & Katzberg, 2012). IVIG promotes rapid 
improvement in 80% of MMN patients (Padua et al., 2005) and is deemed customary for 
this diagnosis (van Schaik et al., 2006). Furthermore, the efficacy of IVIG has been 
demonstrated in seven randomized controlled studies with CIDP (Patel et al., 2010) as 
well as the Immune Globulin Intravenous For Chronic Inflammatory Demyelinating 
Polyneuropathy (ICE) trial that reported both short and long-term effectiveness (Hughes 
et al., 2008; Patel et al., 2010). IVIG has also demonstrated high tolerability with few 
reported serious side effects in neuromuscular diseases (Nadeau, Bhibhatbhan, 
McDougall, & Toth, 2010).  
How IVIG is administered varies by patient and disease, but in general, requires 4 
to 6 hours, usually a dose of 2 GMs/kg which may be divided into two doses 
administered over a period of 2 days (PNA, 2014). It is possible to give the dose on 
alternate days or over a period of 5 days with treatment typically repeating every 4 to 6 
weeks (PNA, 2014). The treatment experience typically complicates patients’ lives 
regarding scheduling, travel time, high medical costs, and the time commitment of the 
treatment itself. Thus, the treatment experience may negatively influence QOL.  
The World Health Organization Quality of Life Group (1995) defined QOL as 
"individuals' perception of their position in life in the context of the culture and value 
systems in which they live in relation to their goals, expectations, standards and 
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concerns" (p. 405). A person's goals, expectations, and standards for their future may be 
altered and changed because of a diagnosis of a neurological autoimmune disease which 
may in turn influence QOL. Keles, Ekici, Ekici, Bulcun, and Altinkaya (2007) found that 
negative effects of chronic disease bring about profound psychological distress in 
patients. They concluded psychological distress in itself may impact QOL similarly to the 
presence of several chronic diseases. 
Although many articles report on the physical improvements with IVIG treatment 
in neurological autoimmune diseases, little research addresses the problem of the QOL of 
patients who require lengthy treatments of IVIG to manage or improve their condition 
(Padua et al., 2005). Emotional and psychological consequences may occur as patients 
face the ramifications of the IVIG treatment experience, such as side effects, complex 
schedules, lengthy treatment times, and strain on financial resources (Patel et al., 2010). 
The few studies do not cover psychological aspects of QOL or describe patients’ 
responses to the intrusiveness of illness and treatment. Gerschlager and Brown (2002) 
conducted a study with patients diagnosed with stiff person syndrome receiving IVIG and 
found improved health-related QOL. However, this study had a small sample of six 
patients. Additionally, Padua et al. (2005) conducted a pilot study assessing quality of life 
in 25 autoimmune patients receiving IVIG. Using the SF-36, the authors’ findings 
revealed less pain, better upper limb functioning, and improved physical functioning after 
IVIG therapy, but did not indicate reduced psychological distress. In fact, this is the only 
study that examined psychological issues related to IVIG and autoimmune disease.  
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Padua et al. (2005) suggested the necessity of more research on the influence of 
IVIG on the health-related and psychological QOL to extend previous research. The 
authors suggested that there may be several treatment experience factors (direct and 
indirect) affecting patients. My study attempted to fill that gap by examining (a) the 
direct and indirect effects of the IVIG treatment experience on QOL, and (b) the 
influence of illness intrusiveness and personal control as potential mediators of this 
relationship. 
Illness intrusiveness has been demonstrated to be a determining factor in the 
psychosocial effect of chronic disease and treatment (Devins, 1994) as well as a mediator 
of QOL indicators (Poochikian-Sarkissian et al., 2008a). Levels of illness intrusiveness in 
the patient's life can determine outcomes in QOL. Elevated levels of illness intrusiveness 
were found to associate with low QOL in a study of epilepsy treatment groups 
(Poochikian-Sarkissian et al., 2008a). In fact, illness intrusiveness was found to be 
significantly associated with all aspects of QOL in MS patients (Shawaryn, Schiaffino, 
LaRocca, & Johnston, 2002). Included in the construct of illness intrusiveness are the 
stressors brought about by treatment of chronic disease such as financial pressure, 
complex schedules, economic or employment hardship, possible side effects, diminishing 
recreational activities, and dependency on medicine and/or medical personnel (Devins, 
2010), all of which may be caused by IVIG treatment. These findings suggest the value 
of investigating illness intrusiveness as a potential mediator between disease treatment 
(IVIG) and QOL.  
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Personal control refers to a person's expectations regarding their own ability to 
influence results through their own behavior (Rotter, 1990). According to the illness 
intrusiveness theory, personal control over desirable outcomes in life is reduced when 
treatment and disease interruptions affect lifestyle and normal activities (Devins, 2010). 
Personal control may be an important factor in QOL of neurological autoimmune 
patients. For example, Poochikian-Sarkissian et al. (2008a) found that patients who 
perceived control over their disease and treatment reported a better QOL than persons 
who did not perceive control. Gruber-Baldini, Ye, Anderson, and Shulman, (2009) found 
that the relationship between Parkinson’s disease (PD) disability was increased in 
patients exhibiting less internal locus of control. Rotter (1966) suggested that an 
individual can change behaviors if they believe they are controllable. Gruber-Baldini et 
al. (2009) found that patients who believed they could control their behaviors may have 
implemented strategies to maintain optimal function. The authors also suggested that this 
higher level of personal control may have modified the progression of the individual’s 
disability.  
 It is possible that control may influence how a person responds to a chronic 
disease or illness or how they interpret the impact of the disease on their life style. Bishop 
(2005) found that personal control mediated the relationship between impact of chronic 
illness and disability and QOL in a study incorporating a modified illness intrusiveness 
approach with college students with chronic disabilities. Additionally, Bishop, Frain, and 
Tschopp (2008) found the impact of MS symptoms was partially mediated by personal 
control when testing the illness intrusiveness model. The study also suggested a positive 
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relationship between self-management of chronic illness and personal control which 
could suggest the importance of control supporting a patient's ability or motivation to 
intervene for their treatment or communication with physicians (Bishop et al., 2008). 
Personal control may also have an important role in the relationship between illness 
intrusiveness and QOL in MS, MMN, MG, and CIDP patients warranting examining it as 
a potential mediator in my study. 
Studying the relationship of the IVIG experience on QOL is important for a 
number of reasons. The current study provided information regarding the QOL 
encountered by autoimmune patients receiving immunotherapy. Insight into the 
relationship of IVIG with QOL may guide medical personnel in service to these patients 
as they gain a deeper understanding of some of the psychological issues which may result 
from illness intrusiveness potentially mediating the relationship of IVIG on QOL. 
Gaining knowledge about the consequences of illness intrusiveness may aid IVIG nurses 
and medical teams in planning physical or emotional patient interventions to improve 
QOL while a patient is receiving IVIG immunotherapy. Finally, the current study 
contributed to closing the knowledge gap and extending previous limited research 
regarding IVIG and QOL. 
Problem Statement 
Although research demonstrates IVIG is the treatment of choice for the four 
neurological autoimmune diseases examined here, studies are limited and do not reflect 
the possible social and psychological experience of IVIG treatment on QOL for those 
patients receiving this therapy. Although IVIG is common, the high cost of the therapy, 
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complicated schedules, and long hours of infusions may cause disruptions to the lives of 
the neurological autoimmune patients who receive it. Therefore, it was necessary to 
assess the relationship of this particular treatment experience on QOL for patients with 
autoimmune diseases that are treated with this approach (MMN, MG, MS, and CIDP 
patients). Further, it was reasonable to consider illness intrusiveness as a mediating factor 
between the IVIG experience and QOL since research has shown the IVIG treatment may 
mean interruption in activities, schedules, and life plans (Devins, 2010), and it has been 
shown to be a mediator in other chronic diseases (Dancey, Hutton-Young, Moye, & 
Devins, 2002; Devins et al., 1993; Shawaryn et al., 2002).  
Some patients may not be as affected by the potential illness intrusiveness of 
IVIG as others. Considering whether control may be a mediator between illness 
intrusiveness and QOL may shed significant light on why some patients may view 
treatment as intrusive and other patients may not. Personal communication with 
neurologists and IVIG specialist nurses has indicated a need for more in-depth insight 
into the IVIG experience for patients receiving this treatment (C. L. Gooch, personal 
communication, December, 3, 2013; T. Levine, personal communication, June 7, 2012; 
S. McBride, IVIG RN, personal communication, June 18, 2014; K. Clarke, IVIG RN, 
personal communication, May 20, 2014). This study was needed to enhance the limited 
literature regarding the relationship of IVIG and QOL with neurological autoimmune 
patients receiving this treatment. I hypothesized that the study would provide IVIG 
nurses, patients, and physicians a deeper understanding of the psychological aspects of 
the IVIG experience and its effects on QOL.  
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Purpose of the Study 
The purpose of this survey research study was to examine the relationship 
between the IVIG treatment experience (predictor variable) and QOL (outcome variable) 
in neurological autoimmune patients. Illness intrusiveness was investigated as a possible 
mediator between the IVIG treatment experience and QOL in this patient population. 
Additionally, personal control was studied as a potential mediator between illness 
intrusiveness and QOL. There have been no previous studies considering the role of these 
mediators in the relationship between IVIG treatment and QOL. This study was an 
attempt to fill that gap. 
Research Questions and Hypotheses 
This study used a predictive model to examine the strength of the IVIG treatment 
experience in explaining the variance in QOL and to test the mediating influence of 
illness intrusiveness and personal control. Data were collected from a convenience 
sample of MS, MMN, MG, and CIDP patients from PNA who were currently receiving 
IVIG treatment. The following research questions (RQ) and hypotheses were proposed: 
RQ1: Is the IVIG treatment experience (as measured by the Visual Analogue 
Scale) a significant predictor of QOL (as measured by 10 Neuro-QOL scales) in patients 
with autoimmune disorders who receive IVIG treatment?  
H11: IVIG treatment experience (as measured by the Visual Analogue Scale) is a 
significant predictor of QOL (as measured by 10 Neuro-QOL scales) in patients with MS, 
MMN, MG, and CIDP who receive IVIG treatment.  
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H01: The IVIG treatment experience (as measured by the Visual Analogue Scale) 
is not a significant predictor of quality of life (as measured by 10 Neuro-QOL scales) in 
patients with MS, MMN, MG, and CIDP who receive IVIG treatment.   
RQ2: Does illness intrusiveness mediate the relationship between IVIG treatment 
experience and QOL (as measured by -10 Neuro-QOL scales) among individuals with 
autoimmune disease who received IVIG treatment? 
H12:  Illness intrusiveness mediates the relationship between IVIG treatment 
experience and QOL (as measured by 10 Neuro-QOL scales) among individuals with 
MS, MMN, MG, and CIDP. 
H02: Illness intrusiveness does not mediate the relationship between IVIG 
treatment experience and QOL (as measured by 10 Neuro-QOL scales) among 
individuals with MS, MMN, MG, and CIDP. 
RQ3: Does personal control mediate the relationship between illness intrusiveness 
and QOL (as measured by 10 Neuro-QOL scales) among individuals with autoimmune 
disease who receive IVIG treatment? 
H13: Personal control mediates the relationship between illness intrusiveness and 
QOL (as measured by 10 Neuro-QOL scales) among individuals with MS, MMN, MG, 
and CIDP. 
H03: Personal control does not mediate the relationship between illness 
intrusiveness and QOL (as measured by 10 Neuro-QOL scales) among individuals with 
MS, MMN, MG, and CIDP. 
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Theoretical Framework for the Study 
The illness intrusiveness framework guided this research. The framework posits 
disease and/or treatment factors affect illness intrusiveness which then directly affects 
QOL. Illness intrusiveness is the intervening variable between the disease treatment and 
QOL (Devins, et al., 1983; Poochikian-Sarkissian et al., 2008a). According to this theory, 
QOL is compromised when the disease treatment interferes with goals, interests, and 
enjoyable activities. When treatment interferes with positive experiences, the perception 
of personal control is also diminished (Devins, 1994). Ultimately, illness intrusiveness 
directly influences QOL by reducing pleasurable experiences and indirectly by 
decreasing the patient's personal control (Devins, 2010). 
The illness intrusiveness theory has been supported in various studies of different 
patient populations. Overall, research indicates more illness intrusiveness occurs in 
patients with severe disease symptoms (Cina & Clase, 1999; Devins, 2010; Devins et al., 
1996; Devins et al., 1990; Devins, Edworthy, & ARAMIS Lupus State Models Research 
Group, 2000). Furthermore, regarding treatment factors, research shows increased illness 
intrusiveness is correlated with interrupting treatment schedules and side effects 
(Bettazzoni, Zipurski, Friedland & Devins, 2008; Devins et al, 1990; Devins et al., 1983; 
Poochikian-Sarkissian et al., 2008a). Personal control has been found to partially mediate 
the impact of illness intrusiveness on subjective well-being (Poochikian-Sarkissian et al., 
2008a). Finally, evidence supports the premise that disease and treatment impact 
psychosocial results through the indirect effect on illness intrusiveness (Bloom, Stewart, 
Johnston, & Banks, 1998; Devins, 1994; Devins, Beanlands, Mandin, & Paul, 1997; 
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Devins, Edworthy, Guthrie, & Martin, 1992; Mullins et al., 2001). Using the illness 
intrusiveness framework here was appropriate due to potential mediating effects of illness 
intrusiveness on the relationship between IVIG treatment and the outcome QOL. The 
illness intrusiveness framework will be explained in more detail in Chapter 2. 
Nature of the Study 
I selected a non-experimental, correlational survey research design for the current 
study as this was appropriate to assess the relationship between two or more variables 
(Stangor, 2011). The predictor or independent variable was the IVIG treatment 
experience and illness intrusiveness. The dependent or outcome variable was QOL. 
Additionally, mediation analyses were employed to examine if the relationship between 
the predictor variable, IVIG experience and QOL, was mediated by illness intrusiveness 
and personal control. Data were collected from MS, MG, CIDP, and MMN patients 
receiving IVIG treatment at PNA in Phoenix, Arizona. I distributed surveys to those 
patients willing to participate in the study. Data were analyzed using regression analysis 
to assess the direct and indirect effects of illness intrusiveness and personal control on the 
relationship between the treatment experience and QOL. Bootstrapping was used as a 
robust test to measure indirect effects. A correlational, cross-sectional design was the best 
choice for assessing the relationship of the proposed variables as an experimental design 
would be impossible to conduct with this population receiving treatment on different 
schedules and time periods (Trochim, 2006). Disadvantages and limitations associated 
with this type of design are discussed later in this chapter. 
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Definitions 
Autoimmune disease: Autoimmune disease occurs when the immune system 
(autoantibodies) in the body attacks healthy immune cells. It is a chronic disease that 
targets tissue and organ systems, and occurs due to the loss of immune tolerance (Anaya, 
2010).  
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): CIDP is a 
chronic autoimmune disease which is progressive or relapsing. Characteristics may be 
fatigue, muscle weakness, loss of balance and reflexes, and sensory dysfunction 
(Dalakas, 2010; Mathey & Pollard, 2012). 
Illness intrusiveness: Illness intrusiveness is a construct derived from disease or 
treatment interruptions of desirable interests and activities (Devins, 2010). It is a 
mediating variable of chronic disease and/or treatment and QOL (Poochikian-Sarkissian 
et al., 2008a). 
Intravenous immunoglobulin (IVIG): IVIG is a product of the blood developed 
from the serum of 10,000 to 15,000 donors per each lot. It is the select treatment for 
people with antibody deficiency and is given in a variety of neurological, autoimmune, 
and inflammatory diseases because of the immunomodulatory and anti-inflammatory 
properties (Hartung et al., 2009; Jolles, Sewell & Misbah, 2005).  
Multifocal motor neuropathy (MMN): MMN is a progressive immune-mediated 
disease identified by asymmetric weakness in the arms and legs without sensory loss. It 
usually affects the upper limbs more than the lower limbs with neuropathy (Nobile-
Orazio, 2001). 
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Multiple sclerosis (MS): MS is a progressive neurological inflammatory 
demyelinating disease. Functional impairment may include loss of balance, walking 
ability, muscle spasticity, and overall mobility problems (Pike, Jones, Rajagopalan, 
Piercy, & Anderson, 2012). 
Myasthenia gravis (MG): MG is an antibody-mediated autoimmune disease of the 
neuromuscular junction (Dalakas, 2010). It is characterized by muscle weakness and 
fatigability with involvement of the central nervous system (Sitek, Bilińska, Wieczorek, 
& Nyka, 2009). 
Neurological autoimmune disease: An autoimmune disease affecting the central 
or peripheral nervous system (Kamm & Zettl, 2012). 
Personal control: Personal control is also referred to as locus of control. For the 
purpose of the current research study personal control refers to the individual’s 
expectations regarding their own ability to influence outcomes by their own behavior 
(Rotter, 1990). 
Quality of life (QOL): QOL is defined for the purposes of this study as the 
"individual’s perceptions of their position in life in the context of the culture and value 
systems in which they live and in relation to their goals, expectation, standards and 
concerns" (The World Health Organization Quality of Life Group [WHOQOL], 1995, p. 
405). 
Assumptions  
Since the data in this study were collected through a self-report questionnaire, I 
assumed the participating patients were honest in their responses. I described the 
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procedures to protect the confidentiality and anonymity of the patient responses, so that 
they felt more encouraged to respond honestly. Additionally, all participants were 
volunteers and had the ability to withdraw from the study at any time. It was assumed the 
four autoimmune diagnoses examined in this study were representative of neurological 
patients who receive IVIG treatment (Padua et al., 2005). An underlying assumption in 
this study was that QOL will continue to be an important factor to patients receiving 
medical treatment and to the medical staff serving them. This assumption was supported 
by the current research literature examining QOL in patients with chronic disease.  
Currently, many neurological patients with the medical diagnoses being examined 
in this study receive IVIG treatment. Another assumption of this study was that IVIG will 
continue to be a medical treatment for these diseases, and therefore, such an examination 
of this experience in the patient's lives was relevant. I also assumed that the neurological 
autoimmune patients involved in the study considered their entire IVIG experience when 
answering the questionnaires rather than just one daily event. This was taken into 
consideration in the forming of the single-item IVIG experience visual analogue scale. 
The single-item question has been used at length for assessing QOL and health related 
QOL (Bowling, 2005).  
Limitations 
The study design had inherent limitations that threaten external validity. Given 
that the source of the accessible population is the PNA in Phoenix, Arizona, the sample 
may be representative of the accessible population, while not necessarily being 
representative of the national neurological autoimmune population. Additionally, the 
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sample was selected using patient volunteers between the ages of 18 and 80 who fulfilled 
the criteria of the study based on having one of the four diseases (MS, MMN, MG, or 
CIDP) and were not randomly selected, further limiting external validity. However, I 
reported the demographic characteristics of the sample, so that descriptive comparisons to 
the published literature reporting on patients with the same diagnosis receiving IVIG 
treatment. Proximal similarity is discussed by Trochim (2006) as another approach to 
generalizability which was a relevant consideration after the data was analyzed. It would 
involve thinking of other settings, clinics, or facilities which may have similar IVIG 
treatment infusions centers with similar patients and then developing a theory as to 
whether proximal similarity might exist between persons, settings, or times.  
Regarding internal validity, a limitation of correlational studies is that a causal 
relationship conclusion cannot be drawn among the variables (Stangor, 2011). Although 
the study may observe a relationship between the measured variables, cause cannot be 
concluded without question. It is also possible that reverse causation can occur when 
using mediation since both the mediator and the outcome variable are not manipulated 
(Kenny, 2014). Additionally, spurious relationships are possible due to a common-causal 
variable which may be relevant but is usually unknown to the researcher (Stangor, 2011). 
One method of weakening reverse causation would be to use longitudinal research, which 
was not feasible in my study given my time and resource limitations. On the other hand, 
correlational research is worth doing as it often provides useful information regarding the 
relationships among the variables and directions for future longitudinal research (Stangor, 
2011).  
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Construct validity relates to how well the theoretical concepts are measured by the 
measuring instrument (Frankfort-Nachmias & Nachmias, 2008). Evidence (described in 
detail in Chapter 3) supports the construct validity of the illness intrusiveness instrument 
and its use across a large range of conditions (Devins, 2010; Shawaryn et al., 2002). 
However, discriminative validity across disease stages has not been supported. The 
underlying factor structure supports the invariance of the Illness Intrusiveness Rating 
Scale (IIRS) Confirmatory factor analysis supports the IIRS three factor structure of the 
subscales showing invariance across eight patient groups (Devins, 2010).  
The Neuro-QOL, used to measure the outcome variable, was tested across five 
adult chronic illness samples and two pediatric samples and demonstrated good construct 
validity (Cella et al., 2011). The Multidimensional Health Locus of Control scale 
(MHLC), which will be used to measure control, has shown substantial construct and 
concurrent validity (Wallston, Stein, & Smith, 1994). Psychometric support of these 
measures is also detailed in Chapter 3. 
Delimitations 
The patients selected for the current study were restricted to MS, MMN, MG, and 
CIDP patients between the ages of 18 and 80. The participants were receiving IVIG 
treatment at PNA in Phoenix, AZ. Some patients fitting the criteria may have chose not to 
participate, which would affect how well the final sample of the participating IVIG 
patients represented those who typically attend the treatment facility. Data were collected 
using self-report questionnaires written in English requiring respondents to be proficient 
in reading and understanding English.  
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An experimental or quasi-experimental design was not feasible. Therefore, there 
may have been a selection bias of the participant pool which could be a threat to internal 
validity, particularly given that there was no comparison group (i.e., patients receiving 
another form of treatment). A cross-sectional design was justifiable, given that (a) there 
was an accessible population meeting the sampling criteria, (b) this particular medical 
treatment is being used more often with these diagnoses, and (c) that there has been no 
research assessing the relationship between the IVIG treatment experience and QOL 
(PNA, 2014). One of the theoretical frameworks that might be related to this area of 
study in the future is coping theory (Folkman et al., 1986) as patients may indeed require 
coping skills and abilities while undergoing this often on-going medical treatment. This 
was considered during the design of the study but was eliminated as it would expand the 
scope and length of the dissertation. 
Significance 
I examined MS, MMN, MG, and CIDP in this study, and they fall into the four 
distinct general categories for neurologic autoimmune diseases (Dalakas, 2004). The loss 
of immune tolerance characterizing these diseases results in changes in mobility and life 
styles. Research shows people living with these four neurological autoimmune diseases 
indicate a lower QOL than healthy individuals (Benito-Leόn, Morales, Rivera-Navarro, 
& Mitchell, 2003; Cocito et al., 2006; Mitchell, Benito-Leόn, González, & Rivera-
Navarro, 2005). These conditions, once thought to be untreatable, are now being treated 
with IVIG on a short and long term basis. IVIG has shown positive effects on the 
physical aspects of neurological autoimmune disease, but there is not research 
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illuminating the psychological effects of the treatment experience. This study provides 
information useful to the providers regarding the IVIG experience as it relates to the 
psychological aspects and health related QOL. While shown to be beneficial, IVIG is 
costly and may or may not be covered by insurance companies. This in turn can 
contribute to psychological stress for the patient.  
As a result of the findings of the study, interventions might be planned based on 
the understanding about some of the patient's perceptions of their IVIG experience and 
how this experience has affected their daily lives (K. Clarke, personal communication, 
May 21, 2014). It is very possible that results of this study would be of interest to an 
IVIG nurse association and could be disseminated through writing or public addressing 
such a group (C. Gooch, K. Clarke, & S. McBride, personal communications, December, 
2013 through May 2014). Presenting the results of this research might very well provide 
needed data to assist the medical staff in accommodating some patient related needs for 
scheduling, etc. Both nurses and neurologists have expressed interest in results from such 
a study, and so I plan on presenting the work after completing the study.  
Implications on Social Change 
The results of this study could contribute to positive social change by providing 
knowledge of IVIG and QOL and subsequently influencing policy makers to evaluate and 
increase the availability of this medical treatment. The nursing staff and physicians I have 
interviewed maintain there are many rules and regulations as well as availability which 
make infusions sometimes challenging (C. Gooch, K. Clarke, & S. McBride, personal 
communications, December, 2013 through May 2014). Part of the problem according to 
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staff is that there is little research available documenting the relationship of IVIG 
experience to QOL.  
It is not unreasonable to assume that even pharmaceutical companies may be 
interested in the results of this study. For example, Biofusion, a pharmaceutical 
distribution company employs a patient advocate who travels to various locations 
assisting patients needing this treatment (S. McBride, personal communication, May 18, 
2014). Understanding the relationship between IVIG and QOL, particularly the role of 
illness intrusiveness in this relationship, could provide information needed for a medical 
staff to develop interventions which might have an effect on the patient's ability to cope 
with those life interruptions. For example, perhaps such knowledge would guide the 
medical team to adjust schedules to decrease the intrusion on employment or leisure 
activities or provide counseling to assist patients in coping with the life changes.  
The study has positive implications for social change for both patients and 
medical personnel. Social change may occur when medical teams, families, physicians, 
and insurance companies have a deeper understanding of the relationship of this 
treatment on QOL in neurological autoimmune patients and act on that understanding. 
Walden University (2013) deems "positive social change results in the improvement of 
human and social conditions" (p. 13). This study has the potential of positive social 
change by contributing to the dignity and understanding of the effects of IVIG treatment 
on the QOL in the lives of MMN, MG, MS, and CIDP patients through making results 
available to various stakeholders. Results of this study will be distributed to the staff at 
PNA where the nursing staff, physicians, and research coordinator have been supportive 
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and are anticipating results. Members of the IVIG infusion nurses’ association have also 
expressed a desire for a presentation of results through speaking at their yearly meeting 
held at different locations in the United States (K. Clarke, personal communication, May 
20, 2014; S. McBride, personal communication, June, 2014). It may be possible that 
Gamunex (one of the types of IVIG) may be interested in having me present the results of 
the study (T. Levine, personal communication, May 20, 2012). Biofusion, a 
pharmaceutical distribution company which provides IVIG across the United States for 
those receiving IVIG at home, may be interested in the results of the study as well as they 
have shown concern for the well-being of IVIG patients by providing a patient advocate 
for assisting patients in coping with the IVIG experience. 
Summary 
Literature has established the neurological autoimmune diseases are debilitating 
physically and psychologically. Research has demonstrated MS, MMN, MG, and CIDP 
experience a lower QOL compared to healthy individuals (Erdmann, Lindeman, Cats & 
van den Berg, 2010; Kargiotis et al., 2010; Leonardi et al., 2010; Westblad et al., 2009). 
Consequences from neurological autoimmune disease usually mean problems in the 
central and/or peripheral nervous system. Although many of these diseases can be 
effectively treated with IVIG, the high cost of medicine and interruption to life style can 
negatively impact the patient's ability to participate in social events, family interactions, 
and employment. The effect of this treatment experience may in turn lead to illness 
intrusiveness which may negatively impact a patient's QOL. The fact that only one study 
exists examining IVIG and QOL with these four neurological autoimmune diseases 
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(Padua et al., 2005) and no studies exist examining the relationship between IVIG, illness 
intrusiveness and QOL in these diseases leaves a serious gap in the literature that causes 
medical staff to speculate rather than make informed decisions regarding treatment plans 
and care in the effort to maximize this medical treatment. It was imperative that the 
relationship of illness intrusiveness, IVIG treatment, and QOL was examined in hopes of 
better understanding neurological autoimmune patients. This study hypothesized that 
illness intrusiveness plays an important role in the relationship between IVIG treatment 
and QOL in neurological autoimmune patients with MS, MMN, MG, and CIDP. 
In Chapter 2, I provide a review of current literature regarding neurological 
autoimmune diseases, QOL, IVIG treatment, and Illness Intrusiveness. In Chapter 3, I 
explain the method and research design and the research questions and hypotheses. I also 
discuss data collection, sampling method, instrumentation data analysis, and ethical 
protection of participants. 
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Chapter 2: Literature Review 
Introduction 
It is estimated that 23.5 million individuals in the United States endure 
autoimmune disease, and the prevalence is increasing (USDHHS, NIH, 2005). 
Autoimmune diseases can be viewed as a group of related disorders with common 
characteristics that can be studied together or separately. They are a burden to individuals 
and society, reducing QOL and increasing medical costs (NIH, 2005). The study focused 
on autoimmune diseases. 
Currently, there is no known cure for most autoimmune diseases, such that large 
numbers of patients face a life of chronic disease and treatments. Autoimmune diseases 
can lead to loss of mobility, sensory and nerve loss, pain, and damage to tissues or cells, 
which may lead to interferences in the individual's interests and activities (Devins, 2010). 
This interference may lead to illness intrusiveness (Devins et al., 1990; Poochikian-
Sarkissian et al., 2008a). Illness intrusiveness is the result of a chronic disease interfering 
with valued goals and activities; it can compromise (QOL) through diminishing positive 
outcomes from valuable or gratifying experiences and by restricting one's ability to avoid 
negative outcomes (Devins, 2010). 
Antibodies are proteins which help an individual to resist infections, but when an 
antibody becomes directed to a person's own tissues it is referred to as an autoantibody 
(USDHHS, NIH, 2012). IVIG is common in the treatment of autoimmune diseases (i.e., 
diseases where antibodies have become autoantibodies) (Dalakas, 2004). Although the 
25 
 
medical efficacy of IVIG has been established (Dalakas, 2008; Hughes, 2008; Hughes et 
al., 2009), there is little research regarding the effects of the IVIG treatment experience 
on QOL. IVIG will be discussed in depth in this chapter.  
In this chapter, I review IVIG treatment in autoimmune neurological disorders, 
QOL and illness intrusiveness in autoimmune diseases, and explore the role of the 
variable personal control on the relationship between illness intrusiveness and QOL. My 
review will include information regarding the physical, mental, and social domains of 
QOL as indicated in the Neuro-QOL instrument which was used in this study. The review 
will also include information on IVIG and the four autoimmune diseases being compared: 
MS, MMN, CIDP, and MG. Although there are several studies relating to illness 
intrusiveness, QOL, and (Devins, Seland, Klein, Edworthy, & Saary, 1993; Shawaryn et 
al., 2002), there have been no studies examining the relationship of illness intrusiveness 
and IVIG treatment experience with this population. Furthermore, there have been no 
studies found examining illness intrusiveness and IVIG in MG, CIDP, or MMN patients.  
The search strategy included the following search engines: PubMed, the Walden 
Library dissertation database, ProQuest Dissertations, Thoreau Walden University 
Discovery Service, PsycARTICLES, Google Scholar, and EBSCOhost Academic Search 
Complete. Topics researched included: illness intrusiveness, autoimmune diseases, 
intravenous immunoglobulin treatment in autoimmune diseases, chronic disease, multiple 
sclerosis, multifocal motor neuropathy, chronic inflammatory demyelinating 
polyneuropathy, myasthenia gravis, depression, social support, and perceived control. 
Although the majority of the research focused on articles from 2002–2012, in some cases 
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seminal articles relevant to major concepts or variables were reviewed. Early illness 
intrusiveness research studies from 1990–2002 were important in establishing seminal 
findings related to the construct of illness intrusiveness and some chronic illnesses. 
Although there were articles relating to IVIG and the medical components of QOL, there 
was a scarcity of research on IVIG and QOL. Therefore, studies were examined that 
looked at depression, social support, and control often associated with chronic disease in 
general.  
Autoimmune Disease 
The human body is defended against invading pathogens such as viruses, 
parasites, and bacteria by the immune system (Jäger & Kuchroo, 2010). The ability of the 
immune system to recognize self from nonself is required in order for unwanted 
pathogens to be cleared effectively (Jäger & Kuchroo, 2010). Immune cells that are self-
reactive and are not eliminated present danger to the individual’s health and 
autoimmunity can develop (Jäger & Kuchroo, 2010). A deficit in immunological 
tolerance to self-antigens signifies the beginning of autoimmune disease (Anya, 2010). 
Damage occurs through T cells and B cells in the preclinical stage of the pathophysiology 
of autoimmune disease (Anaya, 2012). Autoimmune diseases are usually chronic and 
heterogeneous, directed at organ systems as well as specific organs (Jäger & Kuchroo, 
2010). An example of an autoimmune disease attacking a specific organ is found in Type 
I diabetes, whereas lupus erythematosus is an example of an autoimmune disease in 
which the self-antigen extends through the body inflaming tissue in many different 
organs (Jäger & Kuchroo, 2010). There are indications that autoimmune diseases share 
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common origins as they often have some of the same clinical symptoms, predisposing 
genetic factors, and similar physiopathological mechanisms (Anaya, 2012). Interestingly, 
autoimmune diseases attack women disproportionately, and are a significant cause of 
death in middle-age women (Anaya, 2012). For example, 80% of the 5% who contract 
autoimmune disease worldwide, are women (Fairweather, Frisancho-Kiss, & Rose, 
2008). 
Multiple Sclerosis (MS) 
Multiple sclerosis (MS) is an inflammatory neurological disease of the central 
nervous system, with genetic and environmental influences affecting the risk of 
contracting the disease (Hemmer, Nessler, Zhou, Kieseier, & Hartung, 2006). It has long 
been accepted that MS has two components, an inflammatory demyelination stage which 
occurs early in the disease and a neurodegeneration stage which transpires as a result of 
repeated inflammation (Charil & Filippi, 2007). However, Charil and Filippi (2007) 
posited that both demyelination and neurodegeneration may occur simultaneously. 
Regardless of when they occur in MS (early or late in the disease process), they are 
important aspects of this chronic disease. Demyelination is defined as damage to the 
myelin with preservation of the axons caused by diseases that destroy the myelin sheath 
and/or the cells which create them (Love, 2006). Demyelination can occur in the brain, 
optic nerves, spinal cord, and brain stem in multiple sclerosis (Trapp & Nave, 2008).  
The other primary disease process is neurodegeneration which is referred to the 
progressive loss of neuron function or structure and sometimes neural death (Choudhury, 
Saytode, & Shah, 2014; Koch, Uyttenboogaart, van Harten, Heerings, & De Keyser, 
28 
 
2008). Chronic progression of the disease may be related to the axonal degeneration 
where the relapses in MS are most often attributed to the central nervous system (CNS) 
inflammatory demyelination (Koch et al., 2008). Chronic fatigue often accompanies MS 
and may be affiliated with the chronic progression in the disease (Koch et al., 2008).  
Research has found that individuals living with MS, MG, CIDP, and MMN have a 
lower QOL than healthy populations (Benito-Leόn et al., 2003; Cocito et al., 2006; 
Mitchell et al., 2005) and fatigue, pain, personal control, and social support may all play a 
role in the QOL of these patients. For example, fatigue is a disease outcome of all four 
diseases which were examined in this study as it relates to QOL in autoimmune patients 
(Greim, Engel, Apel, & Zettl, 2007; Merkies & Faber, 2012). If the illness intrusiveness 
from MS, CIDP, MMN, and MG is such that desired activities are diminished, it may 
follow that patient’s QOL might also be negatively influenced. Although Shawaryn et al. 
(2002) showed illness intrusiveness mediated the QOL and MS relationship, research 
regarding illness intrusiveness and QOL in CIDP, MMN, and MG has not been presented 
in the literature. A goal of the present research study was to extend research further by 
assessing the QOL of MS, MMN, CIDP, and MG patients receiving IVIG and 
determining whether illness intrusiveness mediated the relationship between IVIG and 
QOL.  
Myasthenia Gravis (MG) 
MG is an acquired chronic autoimmune disease characterized by fatigue and 
weakness with a prevalence of about 200 people per million in the United States 
(Meriggioli & Sanders, 2009). This neuromuscular junction disease demonstrates 
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painless voluntary muscle weakness in specific muscle groups, which can include ocular 
weakness in 85% of individuals with the disease (Maggi & Mantegazza, 2011). Other 
symptoms may include problems in swallowing and respiration (Kulaksizoglu, 2007). 
The disease course is unpredictable and diagnosis can be difficult due to similarities to 
other diseases and variable disease characteristics (Juel & Massey, 2007). MG is a 
disease which most often appears in women younger than 40 and after age 50 may occur 
more often in men (Juel & Massey, 2007). Fatigue can change by the hour and/or day and 
sustained exercise may exacerbate the fatigue (Juel & Massey, 2007). Daily activities 
may become difficult to sustain, respiratory infections can be lethal, and QOL minimized 
as a result of MG (Kulaksizoglu, 2007). IVIG provides short term improvement in 
strength and is used for MG crisis and exacerbations (Juel & Massey, 2007; Maggi & 
Mantegazza, 2011). 
Multifocal Motor Neuropathy (MMN) 
MMN is an immune-mediated chronic disease with demyelination of the motor 
nerve fibers and a prevalence of 1–2 per 100,000 (Nobile-Orazio et al., 2005). 
Progression is usually slow with a stepwise course with partial conduction block (Nguyen 
& Chaudhry, 2011). It is characterized by multifocal weakness of limbs without loss of 
sensation (Erdmann et al., 2010), but has been reported to have more asymmetric 
weakness in the upper extremities rather than the lower (Erdmann et al., 2010). In 
addition to limb weakness MMN patients often have activity restrictions and problems 
with general functioning including difficulty moving and walking, muscle strength 
problems, and interacting in activities of enjoyment which affect QOL (Erdman et al., 
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2005). The majority of MMN patients have problems with dexterity making daily manual 
jobs challenging (Van den Berg-Vos et al., 2002a). According to Nguyen and Chaudhry 
(2011), MMN is a treatable disorder which responds well to IVIG and affects men more 
than women (3:1 ratio). Treatment can sometimes be long-term with IVIG transpiring 
over years (Van den Berg-Vos, Franssen, Wokke & Van den Berg, 2002b). IVIG is the 
primary treatment which is effective in this immune mediated disease, but it is expensive 
and the required frequency of treatments are burdensome for patients to maintain (van 
Asseldonk, Granssen, Van den Berg-Vos, Wokke, & Van den Berg, 2005).  
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 
CIDP is an autoimmune disease usually manifesting during the ages of 30 to 60 
(Dalakas, 2010). Seminal research indicates CIDP became a recognized medical entity in 
1975 when the disease characteristics were originally defined (Dyck et al., 1975). 
Symptoms are often progressive advancing over a minimum of 2 months and are 
characterized by sensory dysfunction, progressive muscle weakness usually symmetric, 
with loss of balance, and absent or reduced tendon reflexes (Dalakas, 2010; Mathey, & 
Pollard, 2012). Dalakas (2010) indicated the disease can be marked by periods of 
spontaneous remission causing re-evaluation of treatment. CIDP can cause permanent 
disability when it occurs in children, although response to treatment may be more 
favorable than with adults (Dalakas, 2010). Diagnosing CIDP correctly at the outset 
through electrophysiological testing, cerebrospinal fluid analysis, and/or nerve biopsy is 
vital to determine responsiveness to immunotherapies and distinguish CIDP from those 
autoimmune disorders which do not respond to immunotherapies (Dalakas, 2010). 
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Finally, treatment goals for CIDP include improving motor performance, strength, 
balance, and QOL which is approached through corticosteroids, IVIG or plasmapheresis 
(Dalakas, 2010). Since long term therapy is often necessary for CIDP patients, it is 
reasonable to imagine QOL may be compromised in these individuals.  Since this study 
specifically relates to patients with CIDP who are receiving IVIG treatment, it is 
important to note that the ICE study suggested IVIG as a first line therapy for CIDP and 
led to a Federal Drug Administration (FDA) approval of one particular brand of IVIG for 
CIDP patients (Hughes et al., 2008). The cost and availability of IVIG may limit this 
potential therapy for some CIDP patients (Mathey & Pollard, 2012). 
Intravenous Immunoglobulin (IVIG) as a Treatment for Autoimmune Disease 
Antibodies are proteins which help an individual to resist infections, but when an 
antibody becomes directed to a person's own tissues it is referred to as an autoantibody 
(USDHHS, NIH, 2012). Autoantibodies are the root of autoimmune disease and of the 
intrusive debilitating factors and treatments those diseases can bring on the individual. 
IVIG is a preparation produced from over 5,000 blood donors providing healthy 
antibodies for treatment in patients with a variety of diseases (Jolles et al., 2005). A large 
pool of donors provides a larger number of diverse immunoglobulins (IGG) compared to 
one individual, which may be instrumental in the treatment result (Stangel, Hartung, 
Marx, & Gold, 1998). It is given as replacement plasma protein therapy to individuals 
who are lacking and deficient in antibodies (Stangel et al., 1998). IVIG is used as 
treatment for neurological disorders and autoimmune diseases that impact the peripheral 
nerves, central nervous system, or neuromuscular junction, including the four diseases 
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that were the focus of this study, CIDP, MMN, MG, and MS (Dalakas, 2004). The IVIG 
is administered as replacement treatment every 3 weeks in the amount of 200–400 mg/kg 
body weight. A high dosage of IVIG (2 g/kg/month) is given to individuals with 
inflammatory and immune disorders usually in two doses on alternate days or if there is a 
concern about potential side effects, it may be given over 5 days (Jolles et al., 2005).  
The action mechanisms by which IVIG works seems to depend on the disease 
pathogenesis and the dose of the immunoglobulin given to the patient (Jolles et al., 2005). 
It is believed IVIG produces therapeutic effects by influencing certain elements of the 
immune system including macrophages, B-cells, cytokines, T-cells, complement and 
cellular adhesion molecules (Jacob & Rajabally, 2009). Hartung (2008) explains IVIG 
contains IgA and IgM antibodies, Th2 cytokines, and cytokine antagonists which may 
support the therapeutic results. IVIG inactivates auto-reactive T-cells and restores the 
balance of cytokines (Hartung, 2008). Importantly, IVIG is hypothesized to block auto-
immune T-cells from entering the blood-nerve barrier (Hartung, 2008). IVIG is also 
surmised to prevent harmful activity in production of B-cells and may affect innate 
immunity. Finally, IVIG results in a down-regulation of the immune response which may 
be beneficial in neurological immune diseases and neuromuscular disorders (Hartung, 
2008). 
The benefits of using IVIG in therapy include a broad action range and safety. It 
is able to block B-cells, T-cells, macrophages, and antibodies at various sites which are 
particularly useful in neurological inflammatory conditions (Hughes, 2008). IVIG does 
not have the side effects exhibited by steroids or immunosuppressive therapy but patients 
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can experience some mild or moderate side effects which may include headaches, fever, 
or a stiff neck following the infusion (Jolles et al., 2005). According to Jolles et al. 
(2005), slowing or adjusting infusion time, and giving pre-medications can help to 
minimize the side effects. Problems that can arise with IVIG treatment include cost and 
shortage of supply (Hughes, 2008). 
Historically, there was a shortage of IVIG worldwide in 1997 due to an 
interruption in production caused by the more rigorous U. S. Food and Drug 
Administration regulations (Feasby et al., 2007). A similar shortage of IVIG has not re-
ensued but this continues to be a very expensive therapy, and rising costs have caused 
insurers and hospitals to question the cost effectiveness of the treatment (Jordan, Vo, 
Peng, Toyoda, & Tyan, 2006). In fact, the cost is considered the major negative aspect of 
IVIG treatment (Griffin & Hughes, 2009). The cost of IVIG has been on the rise and as 
of 2010 was approximately $70.22 per gram. The cost of an IVIG infusion (usually 
divided into two doses over a 2 day period) totaling 2.0 grams per kilogram (g/kg) of the 
average adult individual’s body weight of 70 kilograms, would be about $10,000.00 
(Winters, Brown, Hazard, Chainani, & Andrzejewski, 2011.). Private insurance will pay 
for IVIG in many cases depending on the diagnosis. Medicare will pay for IVIG to be 
received for some diagnoses, but will allow only primary immune deficiency disease to 
be covered in the home setting. The at-home coverage is for the medication only and not 
for the nursing care required. Some IVIG will be covered by Medicare under part D, but 
again it depends on the plan. Medicare will cover 80% of IVIG in the hospital setting for 
diagnoses allowed for this treatment and if the physician states it is medically necessary 
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which means that the patient pays the remaining 20% out of secondary insurance or out 
of personal resources (Medicare, 2014). 
The Effects of IVIG Treatment 
Since most autoimmune diseases have the comparable problem of one part of the 
body immune system attacking another part of the body instead of protecting the body 
against viruses and bacteria, IVIG is helpful in that it is considered to contain antibodies 
which seems to block the attack (PNA, 2014). The overall length of treatment with IVIG 
for neurological autoimmune patients varies with the individual’s diagnosis and the 
response to the therapy. For example, for some autoimmune patients treatment is repeated 
every 4 to 6 weeks and for others it may be a few weeks or months (PNA, 2014). 
Usually, for a 2-GMs/kg dose given over a period of 2 days each daily treatment would 
be approximately 4 to 6 hours in length (PNA, 2015). Each patient is evaluated regularly 
by the neurologist to determine the effectiveness of the treatment. In some cases, patients 
continue to receive this IVIG therapy for a lifetime. Immediate physical results of an 
IVIG treatment also may differ with the individual patient response. For example, some 
patients experience physical benefits (improved strength or mobility) the same day of the 
treatment while others may not experience physical improvements for a day or two 
(PNA, 2015). Benefits from IVIG include less fatigue, improved strength, and increased 
mobility and less dependency for activities of daily living (PNA, 2014). Potential 
negative side effects may be headache, chills, and fever with serious side effects such as 
renal failure and thrombotic events being rare (Hughes & Lunn, 2012). 
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Measurement of IVIG Treatment Experience 
Measurement of IVIG treatment experience/impact was accomplished through a 
single item question in a Visual Analog Scale. This appeared to be the best option as 
there is no measurement already created to examine the IVIG experience, and the 
experience consists of a number of disparate dimensions, such as timing/schedule 
intrusion, cost and discomfort, in addition to the benefits (decreased symptoms, better 
mobility, etc.). Using this measurement will allow the patient population to consider their 
overall IVIG experience after thinking about all these factors. This possibility has been 
discussed with the medical experts who agreed this would be a feasible alternative to 
creating a new measurement. Academic experts were consulted who thought this would 
be the best option since there is not an instrument available (C. Gooch, K. Clarke, & S. 
McBride, personal communications, December, 2013 through May 2014). 
Single item questions have been useful in research especially when there is 
limited time or the need to reduce patient burden (Davey, Barratt, Butow, & Deeks, 
2007). A single item Visual Analog Scale (VAS) was used to measure anxiety with good 
comparability to a longer STAI instrument (Davey et al., 2007). Patients are able to mark 
their subjective responses on the VAS A and it is simple and rapidly administered. The 
VAS-A computerized single-item measure was shown to be a beneficial tool self-rating 
state anxiety (Abend, Dan, Maoz, Raz, & Bar-Haim, 2014). A different study found a 
single item VAS to have excellent reliability, good validity and responsiveness compared 
to multi-item questionnaires when assessing global quality of life (de Boer et al., 2004). 
Moreover, the single item VAS was found to be the best instrument to assess pain in 
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fibromyalgia patients (Bigatti & Cronan, 2002). In the light of previous literature, it 
seemed reasonable to use this approach for the predictor variable, IVIG treatment 
experience. Recommendations for future research in measurement development are 
presented in Chapter 5.  
Theoretical Foundation 
Two theoretical frameworks were selected to guide the proposed research. Illness 
intrusiveness theory focuses on the extent to which valued interests and activities are 
disrupted by disease factors and treatment (Devins, 2010; Poochikian-Sarkissian et al., 
2008a). Personal control theory focuses on the person’s belief in the ability to control the 
important parts of one's life through their own actions and choices (Rotter, 1966). 
The Illness Intrusiveness Model 
Chronic disease presents challenges such as disability, pain, and symptoms which 
may require patients to surrender jobs resulting in economic adversity, reduce ability to 
participate in enjoyable activities, and institute dependence on medical systems for day to 
day living. These disruptions are considered stressors which interfere with lifestyles and 
psychologically meaningful interests and activities (Devins, 2010). The construct is 
defined as the degree the patient’s disease factors and/or treatment interfere with the 
person’s continued activities or social roles which are important to him in life. Although 
illness intrusiveness is a molar construct, it can have a variety of sources such as loss of 
function, treatment side effects, financial stress due to treatment requirements, and 
lifestyle disruptions (Devins, 2010). The construct of illness intrusiveness arising from 
disruptions caused by illness and treatment interferences in one's lifestyle may result in 
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compromised QOL. The main tenet of the theory is that aspects of the disease and 
treatment reduce QOL through two pathways: decreasing accessibility to pleasurable 
experiences and diminishing the individual’s feelings of personal control (Devins, 2010). 
Illness intrusiveness refers to ways in which disease and treatment interfere with 
the individual’s daily life (Devins et al., 1983). In particular, illness intrusiveness 
considers the extent a particular illness or its treatment may impede the patient's routines, 
opportunities, and goals. Illness intrusiveness arises from functional deficits, anatomical 
changes, and physical limitations (Devins, 2010; Devins et al., 1992; Shawaryn et al., 
2002). Illness intrusiveness may be predicted by physical and psychological factors. 
Snyder, Foley, Farrell, Beier, and Zemon (2013) found depression, anxiety, and disability 
each independently predicted illness intrusiveness. Illness intrusiveness has been applied 
in a variety of chronic disease studies as an important construct ( Beanlands et al., 2003; 
Dancey et al., 2002; Franche et al., 2004; Paukert, LeMaire, & Cully, 2009; Schattner, 
Shahar, Lerman & Shakra, 2010). Early illness intrusiveness studies indicate Devins (the 
author of the illness intrusiveness theory) used QOL and subjective well-being 
interchangeably in the illness intrusiveness model (Bloom et al., 1998; Poochikian-
Sarkissian et al., 2008a). However, over the years Devins’ viewpoint has evolved. 
Currently, Devins (personal communication, June 1, 2014) now views subjective well-
being as one facet of QOL. Additional factors in QOL might be objective QOL (e.g., 
education, owning a home,), utilities (importance the individual places on their life as 
affected by the disease compared to a life free of disease), and health-related QOL 
(treatment side effects, symptoms and/or social and physical difficulties caused by the 
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disease; personal communication, June 1, 2014). In the present study, I specifically 
examined the relationship between the IVIG treatment experience and the health related 
facet of QOL (how the treatment experience has affected symptoms, social and physical 
challenges of the treatment) mediated by illness intrusiveness.  
The illness intrusiveness model does not suggest that disease and treatment have 
direct effects on QOL, but rather the factors associated with the disease or treatment such 
as complicated schedules, side effects, pain, lost time with family, and others impact 
QOL (Devins, 2010). It is a mediating variable between the disease and treatment factor 
and the quality of life of the patient. It is viewed as a stressor prompted by the disease 
and/or treatment experience which endangers QOL. Specifically, disease and treatment 
experience lead to illness intrusiveness and this in turn leads to changes in QOL (Devins, 
1994; Devins et al., 2000; Devins et al., 1990). The theory posits illness intrusiveness is 
an intervening variable between disease circumstances and quality of life (Devins, 1983, 
2010). In other words, Dancey et al. (2002) posited since it mediates between treatment 
conditions and psychosocial influence, illness intrusiveness is considered a primary 
element in the determination of chronic disease impact. In the current study illness 
intrusiveness was assessed as a mediator between the IVIG treatment experience and 
QOL. 
Illness Intrusiveness as a Mediator. Mediation occurs when the relationship 
between the predictor variable (IVIG treatment experience) and the outcome variable 
(QOL) is altered or adjusted by the presence of the mediator variable illness intrusiveness 
(Kenny, 2014; Shawaryn et al., 2002). Illness intrusiveness has been shown to mediate 
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patient adjustment to chronic disease (Devins et al., 1990; Devins et al. 1992; Devins et 
al. 1997). Additionally, Bloom et al. (1998) found illness intrusiveness mediated the 
relationship between disease and treatment and QOL in a study with 308 young women 
with breast cancer indicating a relationship between illness intrusiveness and QOL 
The correlation between QOL and illness intrusiveness has been demonstrated in 
a variety of conditions such as patients with MS (Devins et al., 1996; Mullins et al., 2001; 
Shawaryn et al., 2002; Snyder et al., 2013), young women with breast cancer (Bloom et 
al., 1998), cancer related stressors (Devins et al., 2013), men and women with irritable 
bowel syndrome (Dancey et al.,2002), sleep disorders, and patients with chronic dialysis 
(Mucsi et al., 2004), diabetes patients (Talbot, Nouwen, Gingras, Bélanger, & Audet, 
1999), women with systemic lupus erythematosus (Devins et al., 2000), epilepsy 
(Poochikian-Sarkissian, Sidani, Wennberg, & Devins, 2008b),  and end-stage renal 
disease (Devins et al., 1997).  
Measurement of Illness Intrusiveness. Measurement of illness intrusiveness is 
accomplished through the Illness Intrusiveness Rating Scale (IIRS) which is a short, self-
reporting instrument (Devins, 2010). Originally developed for chronic and life-
threatening illnesses, it can be used for more moderate conditions as well to gain 
understanding about the degree of life disruptions. The IIRS is comprised of three 
subscales: instrumental, intimacy, and relationships and personal development (Devins, 
Bezjak, Mah, Loblaw, & Gotowiec, 2006). The 13 life domains identified under each 
subscale include: instrumental (financial situation, heath, work, and active recreation), 
intimacy (sex life and relationship with spouse), and relationships and personal 
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development (self-expression/self-improvement, family relations, community and civic 
involvements, other social relationships, passive recreation, and religious expression). 
The questions in the 13 life domains request patients to rate the degree the disease and/or 
treatment impede life domains essential to QOL (Devins, 2010; Devins et al., 2006).  
Considering the brevity of the IIRS measure (13 items), Shawaryn et al. (2002) 
concluded that the IIRS could be a helpful screening tool for physicians and clinics which 
encounter time constraints evaluating their patients. Additionally, the IIRS might help 
identify patients who would be in need of additional services due to quality of life 
challenges or disruptions they experience due to disease and treatment. During a time 
when physicians are expected to evaluate high numbers of patients, it may be difficult to 
evaluate all the emotional and physical needs of each patient; therefore, the brief and 
easily administered IIRS may make problem identification for patients at risk more 
expeditious. It may serve to elucidate those individuals who may be experiencing life 
disruptions and intrusiveness from the chronic disease or treatment. 
Chronic Disease and Illness Intrusiveness. The relationship of illness 
intrusiveness and chronic disease has been demonstrated in a number of studies. Previous 
research has shown increased illness intrusiveness with increased disease severity and 
symptoms (Devins et al., 1992; Devins et al., 1990; Devins et al., 1996; Goudsmit, 
Stouten, & Howes, 2009; Musci et al., 2004). Additionally, treatment factors have been 
shown to be affiliated with increased illness intrusiveness (Bettazzoni et al., 2008; Devins 
et al., 1990; Poochikian-Sarkissian et. al., 2008a). Assuaging the effects of disease 
through medical pathways (Poochikian-Sarkissian et al., 2008a, 2008b), or psychosocial 
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techniques reduces illness intrusiveness effects (Bennet et al., 2005; Carter, Bewell, & 
Devins, 2008; Edworthy et al., 2003). Research findings have indicated correlations 
between illness intrusiveness and concepts such as depression, QOL, social support, life 
domains, and control (Dancey & Friend, 2008; Devins et al., 2006; Neri et al., 2010; 
Talbot et al., 1999; Shawaryn et al., 2002). Some studies have suggested that 
psychosocial factors moderated the effects of illness intrusiveness (Beanlands et al., 
2003; Devins et al., 1992; Devins et al., 2006; Franche et al., 2004) while other studies 
indicated that illness intrusiveness is the mediator between the disease and treatment for 
the individual patient (Bettazzoni et al., 2008; Devins, 1994; Devins et al., 2000; Devins, 
Edworthy, Leendert et al., 1993; Devins et al., 1990). Furthermore, early research into the 
construct of illness intrusiveness showed that a significant difference can transpire across 
treatment modalities as in the case of end-stage renal disease (Devins et al., 1990). 
Devins et al’s (1990) study examined patients receiving dialysis in-center, at home 
dialysis and post-transplant patients (N = 200). Their study revealed a significant lower 
level of perceived intrusiveness of post-transplant patients compared to the three dialysis 
groups (continual ambulatory peritoneal dialysis, hemodialysis, and home dialysis). 
However, the three dialysis groups did not differ significantly in overall perceived 
intrusiveness. Another significant finding in this early research study on illness 
intrusiveness was a significant correlation between increased perceived illness 
intrusiveness and lower QOL. Additionally, increased depression significantly correlated 
with higher levels of perceived intrusiveness. Differences in treatment modalities showed 
significant differences in QOL and perceived illness intrusiveness. Life domains most 
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affected were the physical well-being and the work and finances. Research has also 
compared race-related differences in illness intrusiveness in chronic disease. Race-related 
differences have been shown to exist in women with systemic lupus erythematosus (SLE) 
with Caucasian women showing the highest level of well-being and African Americans 
the lowest level (Devins et al., 2000).  
Illness intrusiveness in chronic diseases such as cancer can become prolonged 
over time. Sohl, Levine, Case, Danhauer and Avis (2014) found women experienced 
different levels of illness intrusiveness 2 years after breast cancer diagnosis. They found 
women with low illness intrusiveness were older, did not have children at home, were 
less apt to have a mastectomy or chemotherapy and few reported side effects such as 
pain. Those with higher intrusiveness were identified as having more problems paying for 
basic treatment and lower psychosocial scores. This study supported findings in previous 
studies (Bloom et al., 1998; Devins et al., 2006). Interestingly, some of the Sohl et al. 
(2014) treatment experiences of cancer patients may be similar with IVIG patients, e.g., 
financial cost of the therapy, and insurance issues. Age was found to play an important 
role in the illness intrusiveness of breast cancer with younger women showing 
significantly higher levels of illness intrusiveness affecting sexual relations, pain, and 
side effects of treatment and the ability to perform household chores (Avis et al., 2012). 
Furthermore, the IIRS was used to demonstrate illness intrusion in patients with atrial 
fibrillation (Dorian et al., 2000). 
Receiving IVIG May Influence Illness Intrusiveness. Autoimmune disease 
patients receiving IVIG may experience different treatment modalities such as IVIG in 
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the hospital setting, neurological clinic, or at home which may affect intrusiveness in the 
life domains. Treatment for neurological disorders can impact QOL domains of physical, 
psychological, social, and environmental health (Cella et al., 2012). For example, most 
treatments for neurological disease aim to improve the physical functioning of the 
patient, but the nature of the treatment may interfere with valued interests, activities and 
goals of the patients. Treatments may be painful, time consuming and costly, restricting a 
patient from employment or social responsibilities.  
Requirements of this treatment can change the individual’s lifestyle and range of 
activity participation. For example, IVIG must be administered by medical personnel in 
most cases requiring special environments such as clinics or hospitals. Administration of 
IVIG occurs over a period of 3–5 hours and fluctuates from every 4–6 weeks. Sometimes 
a patient must receive infusions two to three times a week. The frequency of IVIG can 
interfere with work schedules, family routine or pleasurable activities. Transportation to 
and from hospitals or clinics and scheduling may become a challenge which in turn 
interferes with the person’s daily routine and family life. Employment and finances may 
be negatively impacted with IVIG due to interfering infusion schedules (each infusion is 
about 3–4 hours long, sometimes longer). Home administration of IVIG can pose 
psychological, insurance and financial challenges as well.  
In some cases, individuals have physical reactions to the IVIG which may create 
medical complications. Patients require monitoring for side effects which may transpire 
during or after the infusion. Since II is characterized by interference in an individual's 
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way of life and control of positive outcomes (Devins, 2010), administration of IVIG 
treatment sets the stage for illness intrusiveness.  
Personal Control 
The second theoretical framework used in this study was personal control, which 
refers to the individual's belief in the ability to control the important parts of one's life 
through their own actions and choices (Rotter, 1966). Control has been studied in the 
literature at length from links to medical health, substance abuse and psychological issues 
to correlations with other stress related life issues such as unemployment. Kobasa (1979) 
described hardiness as characteristic of personality composed of control, commitment 
and challenge. For example, control is described as one feature of psychological 
hardiness which may assist the individual in coping with workplace stress by behaving in 
ways to reduce stress (Lambert, Lambert & Yamase, 2003). Moreover, the personal 
control component has been found to predict well-being in the workplace (Nayyeri & 
Aubi, 2011). Additionally, personal control has been found to be a resilience factor in 
coping with daily stress with higher levels of control correlating with lower reactions to 
stress (Neupert, Almeida, & Charles, 2007; Ong, Bergeman, & Bisconti, 2005). In 
another study Diehl and Hay (2010) found perceived personal control acted as a 
resilience factor in coping with stress as well as buffering reactions to it. Personal control 
was shown to be a significant predictor of psychological distress for the unemployed 
second only to the financial strain produced in such life situations (Creed & Bartrum, 
2008). In fact, a longitudinal study indicated personal control was an important mediator 
between job loss and poor health and functioning (Price, Choi, & Vinokur, 2002). 
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Personal Control and Chronic Disease. Research has shown personal control is 
an important construct in many chronic diseases. Control beliefs have been demonstrated 
to be important when coping with a number of illnesses such as cancer (Bárez, Blasco, 
Fernández-Castro, & Viladrich, 2007; Henselmans et al., 2010; Henselmans, Sanderman, 
Baas, Smink & Ranchor, 2009; Ranchor et al., 2010) heart disease (Bosma et al., 2005; 
Leong, Molassiotis, & Marsh, 2004), inflammatory bowel disease (Cooper, Collier, 
James, & Hawkey, 2010), parkinson's disease (Gruber-Baldini, Ye, Anderson, & 
Shulman, 2009), dysphonia (Haselden, Powell, Drinnan, & Carding, 2009) and 
adolescents with chronic illness (Meijer, Sinnema, Bijstra, Mellenbergh, & Wolters, 
2002).   
Personal Control as a Mediator in the Illness Intrusiveness Model. One of the 
implications of the illness intrusiveness theory is that personal control is reduced so that 
the individual has more difficulty obtaining positive results or averting negative 
outcomes from experiences (Devins, 2010). The individual’s perception of the illness 
intrusiveness of the IVIG treatment experience as well as the perception of personal 
control related to that experience was an important consideration in the overall picture of 
assessment in this study. The illness intrusiveness model suggests that personal control is 
one of several potential mediators between illness intrusiveness and the outcome variable.  
In a cross-sectional study (n = 237) assessing the relationship of diabetes 
intrusiveness and control to depression in adults results indicated illness intrusiveness, 
and perceived control mediated the relationship between diabetes and depression (Talbot 
et al., 1999). Utilizing a cross-sectional design (Poochikian-Sarkissian et al., 2008a) 
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found perceived control to be a mediator between the impact of illness intrusiveness in 
epilepsy patients and subjective well-being. 
 Seminal research examined the importance of a patient's perception of II and 
control with 35 hemodialysis end-stage renal disease patients (Devins et al., 1983). This 
research study showed significant correlation of patient perception of illness intrusiveness 
and limited control of their life with negative mood and diminished positive mood. 
Control was found to be a mediator in this research study.  
Personal control has been examined across populations and with the relationship 
of disease intrusiveness to the individual. For example, perceived control was shown to 
decrease before and after diagnosis regardless of prognosis with more psychological 
distress in a group of cancer patients, but some control was regained after a year post-
diagnosis and treatment (Ranchor et al., 2010). Additionally, perceived control has been 
shown to affect the reported number and severity of disease symptoms across a variety of 
illnesses such as hereditary heart disease (Hoedemaekers, Jaspers, & van Tintelen, 2007), 
posttraumatic stress disorder after myocardial infarction (Doerfler, Paraskos, & Piniarski, 
2005), osteoarthritis (Rivard & Cappeliez, 2007), women suffering from hot flashes and 
night sweats (Pimenta, Maroco, & Ramos, 2011), and withdrawal symptoms from 
nicotine (Schnoll, Martinez, Tatum, Glass, & Bernath, 2011). Perceived control regarding 
the intrusiveness of a chronic disease is also vulnerable to change with age (Kempen et 
al., 2005) and educational level (Bailis, Segall, Mahon, Chipperfield, & Dunn, 2001). 
Ranchor et al. (2010) concluded perceptions of control vary according to environmental 
influence.  
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Previous research demonstrated that psychosocial well-being was related to 
illness intrusiveness and increased personal control in MS patients (Devins et al., 1993). 
Poochikian-Sarkissian et al. (2008a) also found better psychosocial outcomes and QOL 
when patients believed they had control in the different life domains. Poochikian-
Sarkissian et al. showed patient’s perceived control over the three life domains measured 
by the Illness Intrusiveness Rating Scale (IIRS; relationships and personal development, 
instrumental, and intimacy) positively correlated with psychosocial outcomes and QOL. 
Poochikian-Sarkissian et al. used the IIRS scale to test the illness intrusiveness theoretical 
framework with epilepsy and to measure all three life domains in epilepsy patients who 
had received surgical and pharmacological treatment. Results showed a significant 
correlation with increased illness intrusiveness and decreased QOL but, at the same time, 
depression increased. Importantly, patients who perceived they had control over their life 
domains showed optimistic QOL and stronger psychosocial effects. The author’s path 
analyses supported the influence of illness intrusiveness theory with epilepsy. Certainly, 
this study lends support to the illness intrusiveness theory which posits feelings of 
personal control are reduced when illness intrusiveness is increased. Although the authors 
indicated their study might have been open to compromise with a self-report measure, 
they surmised the study provided more support of illness intrusiveness as a mediator in 
QOL and a determinant of the psychosocial impact of this chronic disease (Poochikian-
Sarkissian et al., 2008a).  
 In other words, when a person believes they have the ability to control their 
valued experiences or life goals, there appears to be fewer negative intrusive 
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consequences from the disease factors (loss of function, fatigue, etc.) or treatment in the 
life of patient. An individual’s perception of whether control lies with themselves or with 
others (health professionals, family, etc.) affects coping with chronic disease as well as 
adhering to treatment regimens (Fioravanti, Casale, Mantegazza, Leonardi, & Raggi, 
2010; Gençöz & Astan, 2006).  
Unpredictable changes in a chronic medical condition can lead to feelings of a 
lack of control in one's life domains. A different study, Poochikian-Sarkissian et al. 
(2008b) examined the relationship of illness intrusiveness and QOL on seizure controlled 
and non-seizure controlled epilepsy patients utilizing the illness intrusiveness framework. 
Low illness intrusiveness and better QOL associated with the seizure free group 
regardless of treatment type while the uncontrolled seizure group associated with a lower 
QOL (Poochikian-Sarkissian et al., 2008b). This study was yet another example 
supporting the illness intrusiveness theory that personal control is diminished with more 
intrusiveness. 
Similarly, autoimmune patients experience unforeseeable physiological variations 
from day to day which may interrupt their life routine or habits (fatigue, difficulty with 
mobilization, pain) thus, diminishing personal control in the three life domains; intimacy, 
relationships and personal development and instrumental. Since autoimmune patients 
receiving IVIG must potentially encounter long hours of infusions, interrupted schedules, 
a generally restrictive therapy environment and loss of valuable activities, it is suggested 
that the patients who experience illness intrusiveness also feel less personal control and a 
detrimental effect on their QOL. Thus, it is clear that the theoretical framework of 
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personal control has been studied in the context health and illness. Since research seems 
to support fewer reported symptoms with increased personal control seemed reasonable 
to surmise personal control may be related to the IVIG treatment experience of 
neurological autoimmune patients.  
Measures of Personal Control. The current study measured the control variable 
with the Multidimensional Health Locus of Control Form C (MHLC). The 18-item form 
C of the MHLC was developed as a condition specific scale which could be adapted to 
various medical conditions (Wallston et al., 1994). It assesses the extent to which an 
individual believes health-related outcomes are the result of chance or luck, their own 
action or behavior of professionals or family (Wallston et al., 1994). Wallston’s (1992) 
modification of Rotter’s (1954) social learning theory posited locus of control indirectly 
influences the individual’s health standing (Wallston, 1994). The MHLC-Form C was 
developed from Rotter’s early work. It was developed so researchers could compare 
patients with two different diseases; a condition-specific scale for locus of control 
suitable for use with any medical condition. 
The factor structure, reliability and validity of the four subscales was established 
from information gained from 588 patients with chronic pain, diabetes, rheumatoid 
arthritis and cancer. The chance and internal subscales are comprised of six items 
whereas the other people and doctors’ subscales have three items. Items are arranged on a 
1 to 6 Likert with 1 representing strongly disagree and 6 representing strongly agree. 
Internal consistency on the four subscales have alpha levels of 0.70-0.71 for powerful 
others, 0.79- 0.822 for chance, 0.85-0.87 for internal and 0.71 for doctors’ subscale 
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(Wallston et al., 1994). A recent study examining the relationship of locus of control in 
patients with sickle cell disease found alpha levels of 0.87 (internal), 0.78 (chance), 0.56 
(doctors), and 0.77 (other people) for the four subscales in the MHLC- Form C (Gibson, 
2014). Concurrent validity was demonstrated for Form C with a sample of rheumatoid 
arthritis patients. Form B and C of the MHLC showed the two chance scales correlated r 
= .65, the Internality subscales r = .59, the Form B Powerful Others r = .55 and Doctors r 
= .38 (Wallston, 2005). Form C also showed concurrent validity with modest correlation 
with Levenson’s scales with chance, other people, and internality (Wallston et al., 1994).  
The MHLC has been utilized with different groups of medical patients. For 
example, the MHLC was used to predict quality of life in Chinese patients with epilepsy 
indicating the importance that patients believe they have a sense of control over their 
medical condition (Au et al., 2002). Waldron et al. (2010) assessed adjustment to spinal 
cord injury and found well-adjusted spinal cord injured patient exhibited more internal 
control using the MHLC. Variants of the MHLC scales have been developed focusing on 
certain health issues but direct comparisons with other scales were not possible since 
scales differed in selected items or wording. Thus, the MHLC-Form C was developed 
specifically as a condition-specific scale adaptable to any health condition. Earlier scales 
such as Levenson’s general Locus of Control I, P, and C scale and Rotter’s I-E scale did 
not include items dealing specifically with health expectations and focused more on 
situational illness beliefs (Wallston, 2005; Wallston & Wallston, 1981). For these 
reasons, the MHLC-Form C is the most appropriate instrument to assess the relationship 
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of personal control in examining the IVIG experience in neurological autoimmune 
patients. 
Quality of Life 
QOL is a multidimensional construct encompassing many domains. For persons 
with chronic disease, these domains may be differentially experienced (Centers for 
Disease Control [CDC, 2011]; Devins, 2010). According to the CDC the definition of 
quality of life encompasses evaluations of both positive and negative features of life. 
QOL may include many domains and elements in life impacted by one’s health including 
ability to function, social interaction, life satisfaction, and psychological well-being, 
(Eastwood, Doering, Roper, & Hays, 2008). QOL of life may also echo life events, life 
experiences, socioeconomic status, and your current stage of life (Sevinc & Akyol, 2010). 
HRQOL involves the individual’s goals and ambitions which may be constrained by the 
course of the disease or treatment (Taylor, Gibson & Franck, 2008). 
Researchers have included the patient’s perceptions of their physical abilities and 
functions in definitions of HRQOL. HRQOL for chronically ill individuals usually refers 
to the individual’s perception of their physical and emotional states of health including 
their evaluation of their own abilities for social and physical functioning in comparison to 
the ideal level of functioning (Megari, 2013). The manner in which a patient experiences 
an illness or treatment can become a feature of their QOL (Megari, 2013). HRQOL is 
accepted as a multidimensional construct with three domains; physical, psychological and 
social. The physical domain includes symptoms and the person’s ability to perform daily 
living activities (Eastwood et al., 2008) well-being to extreme psychological stress or 
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overall mental well-being (Eastwood et al., 2008; Sprangers, 2002) and the social domain 
may include all aspects of social relationships (Eastwood et al., 2008; Sprangers, 2002).  
Extensive research exists regarding quality of life and chronic disease and 
treatment. QOL was found reduced in cancer patients due to limited activities, type of 
surgery or treatment, and psychological factors (Avis, Crawford, & Manuel, 2005; 
Richardson, Wingo, Zack, Zahran & King, 2008;). Disease symptoms and severity of 
disease have been shown to affect QOL in a number of chronic diseases (Hrisanfow & 
Hägglund, 2012; Király & Gondos, 2012; Nagaraj, Taly, Grupta, Prasad, & Christopher, 
2013; Raggi, Leonardi, Bussone, & D′ Amico, 2012; Robb, Cooke, Devins, Young, & 
Joffe, 1997). Research has indicated health-related quality of life is negatively affected by 
the chronic diseases such as heart disease in a study (n = 152) of atrial fibrillation patients 
finding that these patients showed substantially poorer quality of life compared to healthy 
patients in all the domains tested in the SF-36 (Dorian et al, 2000). Continuing, in MS 
patient’s health related quality of life was found to be not only predicted by the physical 
indices and cognitive indicators but also by the patient's perception of the disease as well 
as the intrusiveness of the disease (Shawaryn et al., 2002). 
The World Health Organization (1995) defines quality of life as the "individual’s 
perceptions of their position in life in the context of the culture and value systems in 
which they live and in relation to their goals, expectation, standards and concerns."(p. 
1405). Utilizing this definition, the instrument the WHO recommends to measure QOL 
uses the four domains of social, environmental, physical and psychological health.  
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The Neuro-QOL Instrument 
Some QOL disease specific measures utilized with MS patients include the 
Multiple Sclerosis Quality of Life questionnaire (MSQOL54), the Hamburg Quality of 
Life Questionnaire in Multiple Sclerosis (HAQUAMS) and the Functional Assessment of 
Multiple Sclerosis questionnaire ([FAMS]; Baumstarck, Boyer, Boucckine, & Michel, 
2013). There are no disease specific QOL measures for CIDP, MG, or MMN. It is 
important to use an instrument which is appropriate for all four diseases. The Quality of 
Life in Neurological Disorders (Neuro-QOL) instrument is tailored for patients with 
neurological disorders, and although it is not specific to each particular diagnosis it is 
purposely designed and created for patients with neurological disorders. It was the quality 
of life instrument utilized in the present study.  
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Figure 1. Neuro-QOL domain framework. Adapted from http://www.neuroqol.org. 
Copyright 2008-2013 David Cella and the PROMIS Health Organization on behalf of the 
National Institute for Neurological Disorders and Stroke (NINDS). Reprinted with 
permission.  
 
The National Institute of Neurological Disorders and Stroke (NINDS) sponsored a 
5 year health-related quality of life project to be developed which would be bilingual, 
psychometrically sound and clinically pertinent to major neurological diseases (Cella et 
al., 2011). The Neuro-QOL is brief, valid, reliable, utilizing item response theory. 
Consistency allows cross-disease comparison which makes it particularly applicable for 
the current study. Consistency was achieved through the development and testing of item 
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banks with determinate questions measuring shared concepts relevant to all the chosen 
neurological diseases (Cella et al., 2011). Experts compiled and identified domains of 
HRQL which are most often influenced by a neurological disease and/or treatment such 
as areas of function, symptoms and other important issues relating to neurological 
disorder when developing the instrument. Focus and caregiver groups were also 
conducted when developing questions for the instrument. Qualitative approaches were 
utilized in analyzing the data sources (Cella et al., 2011). The item banks incorporated 
physical health, social health, emotional health, emotional-behavioral dyscontrol, and 
cognitive health items. The Neuro-QOL developers engaged in a series of steps during 
the development process including: engaging patients and medical providers to identify 
potential items of importance and domains through interviews, focus groups and surveys; 
reviewing published literature; identifying gaps and writing new items; identifying 
domain specific items and organizing; revisions by integrating patient and stakeholder 
perspectives; and cultural review and translating to Spanish (Cella et al., 2011). This 
measurement instrument is appropriate for assessing disease burden in neurological 
health populations as well being utilized in research with studies utilizing predictors, 
mediators, and outcomes (Cella et al., 2011).  
For the current study, I employed the short form measures (8–9 items in each item 
bank) of the Neuro-QOL. These short forms were calibrated from the larger item banks 
and were tested with three samples; a clinical panel (n = 553), the general population (n = 
2,113) and a clinical outpatient population (n = 581). Correlations between the short and 
full length form 0.88 to 0.99 and internal consistency on the short forms was 0.85 to 0.97 
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(Cella et al., 2012). The brief measures were able to differentiate those individuals 
reporting health conditions and whether the conditions interfered with routine function 
(Cella et al., 2012). The Neuro-QOL is a standardized assessment which has shown 
validity and consistency in assessing patient reported outcomes regarding disease burden 
and treatment benefits (Cella, 2012). This is an appropriate instrument of measurement 
for examining the IVIG impact experience and QOL in the neurological populations 
selected for the current study. 
Physical Domain of Neuro-QOL. The Neuro-QOL was developed with 
consideration to the physical problems experienced by neurological patients. The 
developers utilized expert groups, literature review and caregiver focus groups when 
selecting the QOL domains to be included in the instrument (Cella et al., 2011). The 
following literature is supportive in explaining the problems neurological autoimmune 
patients experience which have been addressed in the formation of the item banks for the 
Neuro-QOL.  
Physical issues impact the lives of neurological autoimmune patients. Lower and 
upper extremity function controls mobility and is a main symptom of patients diagnosed 
with neurological autoimmune disease. For example, a study of 2,171 patients with MS, 
using a cross-sectional study design, reported that 43% identified walking and mobility 
problems (WMPs) as the aspect of their chronic disease which most negatively affected 
QOL (Pike et al., 2012). Another study (N = 166) using the United Kingdom Disability 
Scale (UNDS) had MS patients rate the most important bodily function. They found that 
lower limb function, which controls gait, was rated most important to these patients 
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(Heesen et al., 2008). Thus, mobility in neurological diseases is ranked as important and 
can cause patients to require more caregiver assistance and primary care intervention 
(Pike et al., 2012). Productivity through employment and work decreases with the 
presence of WMPs by either a reduction in hours or the ability to work at all (Pike et al., 
2012), making the inability to support themselves physically and financially due to 
mobility problems one of the largest problems MS patients face.  
Fatigue is another major concern for CIDP, MS, MMN, and MG patients and 
which may present as motor fatigue while walking and performing activities of daily 
living (Greim et al., 2007; Merkies & Faber, 2012). Fatigue was demonstrated to 
negatively impact QOL in neurological disease populations (Kobelt, Berg, Lindgren, 
Fredrikson, & Jönsson, 2006). The origin of fatigue in neurological diseases is not clear, 
but has been defined as problems in performing and sustaining mental and physical 
voluntary activities (Chaudhuri & Behan, 2004; de Vries, Hagemans, Bussmann, van der 
Ploeg, & van Dorn, 2010). 
Significant correlations have been shown between disability and higher levels of 
fatigue. Pittion-Vouyovitch et al. (2006) found that greater levels of fatigue correlated 
with more disability, increased depression and lower levels of QOL among a sample of 
237 MS outpatients (Pittion-Vouyovitch et al., 2006). Another case controlled cross-
sectional study assessed 113 patients with autoimmune polyneuropathies using the 
fatigue severity scale (FSS scale) and found severe fatigue in 80% of patients, unrelated 
to sensory deficits, and duration of symptoms or general strength (Merkies et al., 1999). 
These patients concurred that fatigue was significantly disabling and it impaired their 
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QOL. Finally, Boukhris et al. (2005) studied 11 CIDP patients whose primary symptom 
was fatigue using the fatigue severity scale (FSS) along with clinical assessment 
examinations. Patients described fatigue to be the main problem interfering with activities 
of daily living and QOL.  
Sleep disturbance is another symptom that can be a problem with various 
neurological diseases. Kaynak et al. (2006) performed a study with 27 MS outpatients 
and found that they experienced more wake time after sleep onset (WASO), more 
periodic leg movements (PLM), and more time in bed (TIB) compared to control 
patients, which led to lower sleep efficiency index (SEI) and sleep continuity index (SCI) 
scores compared to controls. This study supported an earlier study by Ferini-Strambi et 
al. (1994) in which 25 MS patients were compared to a non-MS control group using 
clinical assessments and brain magnetic resonance imaging. Ferini-Strambi et al. (1994) 
found MS patients experienced decreased sleep efficiency and awakened more during 
sleep. Lobentanz et al. (2004) showed marked reduced sleep efficiency in MS patients 
compared to healthy control group (Lobentanz et al., 2004). The study also found that 
greater neurological disability was associated with poorer subjective sleep quality. 
Adding to these studies, sleep apnea has been found in myasthenia gravis (Stepansky, 
Weber, & Zeitlofer, 1997) and excessive daytime sleepiness has been linked to many 
neurological diseases (Happe, 2003).  
These studies provide supportive literature indicating the importance of including 
these particular domains: upper and lower extremity function, fatigue and sleep 
disturbance. The physical item banks of sexual function, and bowel and bladder function 
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were not included in the Neuro-QOL measurement since upper and lower mobility, 
fatigue and sleep disturbance are the most relevant of the physical domain for examining 
the IVIG treatment experience. The Neuro-QOL was developed so that researchers could 
choose the item banks which would be most useful for the purpose of an individual study. 
The Neuro-QOL was not developed as a disease-specific instrument but was created for a 
variety of neurological conditions so the researcher must determine which domains need 
to be assessed for any given neurological disease (Neuro-QOL, 2015). 
Mental Domain of the Neuro-QOL. The mental domain involves a cognitive 
health component as well as an emotional health component. The cognitive component 
subscale measures the patient's ability to plan, keep appointments, control time, and 
accurately manage a checkbook and other important personal documents; the ability to 
think, plan, focus and remember new information; to carry on conversation, organize 
content of communication or make "to do" lists, speak clearly and understand family and 
friends (Neuro-QOL, 2015). The emotional component subscale measures anxiety, 
depression, stigma, affect, and emotional dyscontrol (Neuro-QOL, 2015). 
Cognitive Component. Neurological diseases are often progressive and can 
impair cognition (Chiaravalloti & DeLuca, 2008). Cognitive problems can occur in 
various neurological disorders, but are most often studied in MS. Some of the areas 
impacted in MS include executive functioning and efficiency in processing. During a 
community-based study of 95 MS patients, Drew, Tippett, Starkey, and Isler (2008) 
reported that 17% of MS patients showed problems with at least five measures of 
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executive functions and the majority of participants showed problems in all three areas of 
cognition; general ability, memory, and executive function.  
Paul, Cohen, Gilchrist, Aloia, and Goldstein (2000) performed a controlled study 
with 28 MG patients and 18 healthy subjects assessing cognitive performance. MG 
patients showed a diminished ability to generate word fluency in categories and letters, 
process information and verbal recall of words over five trials (Paul et al., 2000). 
However, there was no significant difference between the patient and control group on 
the percent of retention from the fifth trial recall to the long delay recall (Paul et al., 
2000). Although this particular study concluded MG patients demonstrated significant 
problems with cognitive function in the areas of rapid processing of information, 
response fluency and visual and verbal learning, Paul et al. concluded these problems 
might not interfere with daily functioning.  
Problems in complex attention, information processing speed and memory are 
often symptoms of a neurological disorder (Chiaravalloti, & DeLuca, 2008). These 
authors posited such problems may make daily life challenging as it becomes difficult to 
effectively manage a household, remain actively employed or participate in activities. 
The processing speed and efficiency deficits in MS may impact an individual's ability to 
carry on a small group discussion, speak clearly into a telephone or even make "to do" 
lists. The inability to remember information at a later point in time may hamper the 
person's ability to hold a conversation or communicate in a small group or at work.  
Cognitive function is an item bank of the mental domain evaluated by the Neuro-
QOL measurement tool which was used in this study. It examined patient perceived 
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difficulties in, calculating, planning as well as memory, attention and decision making 
(Neuro-QOL, 2015).  
Emotional Component. A chronic neurological autoimmune disease may 
precipitate stress in the life of the patient which may negatively affect these aspects of 
QOL. As a result of the stress a patient may demonstrate psychological symptoms such as 
anxiety and depression. Depression has been found in high percentages in autoimmune 
diseases (Chen, Jiang, Ouyang, & Chen, 2009). Dantzer, O'Connor, Freund, Johnson, and 
Kelly (2008) reported that exacerbation in autoimmune diseases can lead to depression 
symptoms in susceptible individuals suggesting inflammation may play a critical role for 
the development of depression in the chronically ill neurological autoimmune patient. 
Feinstein and Feinstein (2001) assessed 100 MS patients for major depression using 
interview methods and self-report questionnaires. They found that 73% of the patients 
reported experiencing symptoms during the previous month. Symptoms reported included 
crying (40%), sadness (36%) and irritability (57%). Researchers concluded that although 
MS patients may not be formally diagnosed with major depression, they may have 
symptoms of emotional dyscontrol that impact QOL. In another study depression was 
independently related to lower quality of life after adjusting for fatigue and disability in a 
group of 60 MS patients (Janardhan & Bakshi, 2002).  
Health-related stigma usually is distinguished by a social lack of acceptance of 
individuals who are distinguished by certain health problems (Weiss, Ramakrishna, & 
Somma, 2006). Stigma may impact emotional QOL. Jacoby, Snape, and Baker (2005) 
suggested there are three features of stigma in chronic illness: (a) the degree to which an 
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illness controls one’s identity, (b) the extent to which others have problems 
understanding the symptoms of the disease; and (c) the seriousness of the social 
outcomes. In terms of this definition, these features can be observed in many of the 
neurological diseases. Individuals with neurological conditions may have trouble with 
ambulation, writing, and speech or may need help with activities of daily living. For 
example, considering the four neurological diseases in this study, other individuals or 
members of society in general may have difficulty understanding such symptoms as 
fatigue, slow gait or mobility challenges in CIDP, MS, MG, or MMN. A lack in 
understanding of symptoms may lead to the neurological immune patient being 
ostracized or excluded from social activities or even assume themselves incapable of 
participating in programs and activities due to the stigma. This lack of understanding can 
create stigma surrounding any of these chronic neurological diseases. Stigma may be 
distinguished as self-stigma (self-felt shame or being different) or enacted stigma (actual 
exclusion or discrimination) for individuals with chronic disease (Scambler, 1998).  
Patients with neuromuscular diseases experience intense feelings of stigma and report 
low qualities of life according to one cross-sectional study (van der Beek, Bos, Middel, & 
Wynia, 2013). In addition, this study revealed patients experienced shame and fear of 
stigma more than the realized stigma. Other studies reported stigma has influenced 
quality of life negatively in a variety of chronic diseases (Dancey et al., 2002; Rusch, 
Angermeyer, & Corrigan, 2005; Suurrmeijer, Reuvekamp & Aldenkamp, 2001). 
Emotional QOL may be measured through positive aspects as well. Some people 
report positive outcomes from chronic disease. Positive outcomes such as increased sense 
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of purpose, formation of closer relationships and an increased appreciation for life have 
been reported across a variety of diseases (de Ridder, Geenen, Kuijer, & van 
Middendorp, 2008). Psychologically adjusting to a chronic illness is important to the 
person's well-being, and so positive affect and well-being are also measured as emotional 
components of the Neuro-QOL.  
These studies support the importance of examining the emotional issues 
experienced by neurological patients for which the emotional domain of the Neuro-QOL 
instrument was established to assess. The emotional domain of the Neuro-QOL was 
selected from expert interviews, focus groups and literature review. This domain was 
included in the current study. 
Social Domain of the Neuro-QOL. Neurological autoimmune disorders, through 
their symptoms and as a result of the treatment, may result in changes to the individual’s 
participation in leisure activities as well as adjustments in their socialization processes 
with friends and family. For example, Vanner, Block, Christodoulou, Horowitz, and 
Krupp (2008) conducted a cross-sectional study with a convenience sample of 43 MS 
patients to explore the association between impairment related obstructions with MS 
patients and leisure activity. Their findings revealed higher leisure activity levels 
associated with lower MS impairment barriers. Understanding the patient's ability to 
participate in social activities and their satisfaction with their social roles is important in 
assessing the QOL of patients with neurological disease.  
In sum, the research demonstrates how QOL is affected across a number of 
domains. However, the research is fairly limited to MS patients, and has not been 
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conducted using persons suffering from other autoimmune diseases. The Neuro-QOL 
with its focus on the physical, mental, and social dimensions of most relevance to persons 
with these types of diseases, offers an opportunity to examine these dimensions with 
greater psychometric accuracy. 
IVIG and Quality of Life 
There is considerable research on the use of IVIG in persons with autoimmune 
disorders, but most of these do not include assessments of QOL. In fact, only two studies 
were found which evaluated QOL in patients receiving IVIG, both with small sample 
sizes. Gerschlager and Brown (2002) examined the benefits of IVIG with stiff person 
syndrome (SPS) patients in a small sample of six patients. They used the SF-36, a 
common QOL instrument and a Visual Analogue Scale at the beginning of treatment and 
two weeks after completion of therapy. Results showed significantly improved SF-36 
scores for energy and vitality, pain, social functioning and general mental health. 
Although the researchers concluded that IVIG improved patient’s QOL, it should be 
noted that the sample was quite small. The second study by Padua et al. (2005) evaluated 
the outcome of IVIG in 25 patients with neurological disorders using the SF-36 Italian 
version and the Disability of Arm, Shoulder, and Hand questionnaire (DASH). Results 
showed an improvement in the patient’s physical health related QOL demonstrated by 
less fatigue, improved upper body and limb function and a smaller degree of pain. Since 
the authors noted no changes in mental scores from baseline to follow-up evaluation, they 
concluded IVIG did not improve psychological conditions (Padua et al., 2005). However, 
in evaluating this research study several methodological problems were noted. The study 
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contained a small sample and measurement was 8 days from the original administration 
of IVIG and follow-up measurement. One might suspect that patients would require a 
longer period of time to note any psychological improvement from this type of treatment. 
Another consideration is that the study does not indicate the length of time these 25 
patients had been experiencing the neurological autoimmune disease. This information 
might be relevant in the overall picture. More studies with larger sample sizes may give a 
clearer picture of the effects of IVIG on the psychological features accompanying many 
autoimmune disorders.  
The Influence of Illness Intrusiveness on Quality of Life 
Some studies have shown illness intrusiveness to be an important construct in 
understanding the psychological adjustment of patients who live with a chronic illness. 
Autoimmune disease patients often live with uncertainty with respect to prognosis, 
treatment, and the daily variations of mobility and ability. One interesting study showed 
higher levels of uncertainty and illness intrusiveness correlated with high levels of 
psychological distress (using the SCL-90-R) in a group of MS patients (Mullins et al., 
2001). As the MS patients experienced intrusion into day-to-day living, QOL can become 
compromised because of the uncertainty of diagnosis and treatment, or the intrusiveness 
of the disease. Although the Mullins et al. (2001) study showed higher levels of distress 
was associated with high illness intrusiveness and uncertainty, illness intrusiveness did 
not serve to mediate or moderate in the study, but did show illness intrusiveness directly 
influenced the patient’s psychological adjustment to the chronic disease of MS. However, 
the Mullins et al. (2001) study did not assess the personal control variable which, as 
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discussed earlier, is considered instrumental in the illness intrusiveness theoretical 
framework (Devins, 2010; Poochikian-Sarkissian et al., 2008a; Shawaryn et al., 2002; 
Snyder et al., 2013).  
Summary 
This chapter presented a synthesis of pertinent studies regarding the role of illness 
intrusiveness and chronic disease. Chronic neurological autoimmune disease impacts the 
patient’s life in many ways. IVIG treatment, although preferable in many autoimmune 
diseases, can further interfere normal life, because the treatment itself is complicated, 
expensive, time-consuming, and carries with it serious side effects. Only two studies with 
small samples have measured psychological aspects of the IVIG treatment experience. 
The limited available research regarding the relationship of IVIG and QOL for 
neurological autoimmune patients makes the present study salient for several reasons. 
However, research from a variety of related areas suggests that illness intrusiveness will 
enhance the understanding of the patients’ IVIG experience, and offer insights to 
treatment providers about how to minimize impact on QOL.  
Considerable evidence supported the use of the illness intrusiveness model in a 
broad range of medical diseases (Poochikian-Sarkissian, 2008a). Although illness 
intrusiveness has been established as a beneficial model in different diseases, previous 
research has not evaluated illness intrusiveness and QOL in autoimmune patients 
receiving IVIG treatment. Inclusion of the individual difference construct of control may 
provide insight as to why some autoimmune patients receiving IVIG are able to adjust to 
disease and treatment factors while others have a more difficult time with the 
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intrusiveness of disease and treatment. Chapter 3 provides information regarding 
methodology for the current study. 
68 
 
 
Chapter 3: Research Method 
Introduction 
The purpose of this quantitative study was to determine if the illness intrusiveness 
model (Devins, 1983) mediated the relationship between IVIG treatment experience and 
QOL in neurological autoimmune patients with MS, MMN, MG, CIDP. I also examined 
the mediating effect of control on the relationship between illness intrusiveness and QOL. 
In Chapter 3, I present the research design, sampling method, procedures, 
instrumentation, data analysis, and ethical protection of autoimmune patients 
participating in the study. 
Research Design and Rationale 
A nonexperimental survey research design was chosen to explore the predictive 
strength of the independent variable (IVIG treatment experience) in explaining the 
variance in the outcome variable (QOL) and to test the mediating influence of two 
variables identified as mediators (illness intrusiveness and personal control). A 
nonexperimental design was most appropriate for this study as it allowed for examining 
the predictive relationship between independent variables and outcome variable although 
causal relationships may not be concluded from this design (Frankfort-Nachmias & 
Nachmias, 2008; Stangor, 2011). This design was consistent with the exploration of 
predictive and mediating relationships according to the II theoretical framework (Hayes, 
2013; Kenny, 2014; Stangor, 2011).  
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An advantage of a cross-sectional correlational design is that it permitted me to 
examine behavior in a real-life setting. A disadvantage is that causation cannot be tested 
and internal validity might be decreased (Frankfort-Nachmias & Nachmias, 2008; 
Stangor, 2011). A self-administered survey, paper and pencil research approach was 
employed for obtaining data from a sample of patients with autoimmune disease. This 
approach was chosen because data could be obtained in a timely way (i.e., when the 
individual patient arrived at the IVIG infusion center or by completing the forms on their 
own) since IVIG treatment is administered on individual time schedules.  
This type of design is appropriate when collecting data that are quantified into 
variables or scales using psychometrically sound questionnaires (Vogt, Garnder, & 
Haeffele, 2012). Relationships (direct and mediated) can be examined for strength and 
direction. An advantage of using a survey design is efficiency and a low cost (Vogt et al., 
2012). Other considerations in choosing this design according to Vogt et al. (2012) are 
that data concerning the IVIG treatment experience can best be obtained from the patients 
with briefly answered and structured questions, and an adequate response rate can be 
expected. Although Stangor (2011) mentioned a concern might be with response rate 
when using questionnaires, most patients completed the questionnaire while they were 
receiving treatment which expedited the response rate. Another advantage was that 
information was relayed while the patient was receiving their infusion so that it was 
convenient for the patient. A disadvantage of survey research design is a question of who 
completed the survey (Vogt et al., 2012); however, this problem was addressed in the fact 
that surveys were given to patients as they began their usual IVIG treatment and when 
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they agreed to participate in the study. The following subsections were the variables that I 
examined in this study.  
Demographics 
The variables of interest included: gender (nominal), age (ordinal), disease 
diagnosis (one of the four autoimmune disease categories), length of time since first 
symptoms in months or years (ordinal), employment status (nominal), and length of time 
receiving IVIG treatment in months and years (ordinal). The demographics form is 
included as Appendix A. Data collected were aggregated in order to describe the 
characteristics of the sample.  
Quality of Life 
The Neuro-QOL was used to measure the dependent variable, QOL. It is a set of 
self-report measures that contains 13 tested item banks each with 8 to 9 items. The 
Neuro-QOL was designed for the researcher to choose which item banks are most 
applicable to the population studies. I used 10 of the item banks with a total of 81 items 
in the questionnaires.  
IVIG Single-item Visual Analog Scale 
The independent variable, IVIG treatment experience, was measured using a 
single-item VAS. Patients were able to mark their subjective responses on the VAS and it 
was simple and rapidly administered (Rossi & Pourtois, 2012). The single-item VAS is 
included in the demographics questionnaire in Appendix A. 
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Illness Intrusiveness 
The IIRS consists of 13 items, summed into a single score. The 13 items helped 
patients rate the degree the IVIG treatment interrupted the QOL domains. This measure 
was used as a mediating variable.  
Control 
The MHLC consists of 18 items (Wallston, 2007). The sum of the values circled 
for each item is the score for each subscale. Form C is designed for individuals having 
medical conditions. Wallston (2007) suggests the word "condition" on the form be 
replaced with the medical diagnosis. This study used the term, neurological autoimmune 
disease. Control was used as a second mediating variable.  
Statistical Analyses Plan 
A variation of multiple regression was used to test the predictive and mediating 
relationships between the independent and dependent variables (Baron & Kenny, 1986; 
Kenny, 2014; MacKinnon, Fairchild & Fritz, 2007; Shrout & Bolger, 2002). This 
approach allowed me to examine direct and indirect effects of select variables predicting 
a single outcome. Mediation is a causal model (Hayes, 2013; Kenny, 2014). Hayes 
(2013) hypothesized that a causal chain occurs in mediation where one variable (X) 
affects a second variable (M) which affects the third variable (Y). The intervening 
variable, M, is the mediator which mediates the relationship between the predictor and 
the outcome (Hayes, 2013). The direct effect is the path between X and Y without 
traveling through M (Hayes, 2013). The indirect effect is the path from X to Y through M 
which is considered the amount of mediation or the effect showing X leads to Y through 
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M (Hayes, 2013; Kenny, 2014). Current research indicates that most scholars of 
mediation analysis no longer require evidence of an association between X and Y prior to 
testing for mediation or indirect effects (Cerin & MacKinnon, 2009; Hayes, 2009; 
Rucker, Preacher, Tormala, & Petty, 2011; Zhao et al., 2010). PROCESS was used in 
SPSS to estimate the coefficients of the model, analyze, and interpret the direct, indirect, 
and total effects (paths a, b, ab, c, cʹ), and the Bootstrap confidence intervals as well for 
several different types of effect sizes (Hayes, 2013).  
Bootstrapping was used to test the intervening variable since research has shown 
bootstrapping is a robust and valid method of testing the effect of intervening variables 
(Hayes, 2009; Preacher & Hayes, 2008; Williams & MacKinnon, 2008) and may be 
advantageous over the Sobel test as it requires no assumption about the shape of the 
sampling population (Hayes, 2009). In addition, simulation research has indicated the 
Sobel approach has low power and produces less accurate confidence intervals compared 
to other methods (Hayes, 2013; MacKinnon, Lockwood, & Williams, 2004). In other 
words, the Sobel approach is less likely to recognize the impact of X on Y through M 
(Hayes, 2013). Bootstrapping constructs a representation of the sampling distribution 
through resampling with replacement that then is used to create the confidence interval 
(Hayes, 2013). Moreover, power is higher when it is employed to test a hypothesis and in 
mediation analysis is more recommended than other methods for inference regarding the 
indirect effect (Hayes, 2013).  
The predictor variable in this study was IVIG treatment experience and the 
outcome variable was QOL as measured by the 10 Neuro-QOL scales. Proposed 
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mediators were illness intrusiveness and control. Use of PROCESS, which employs 
ordinary least squares (OLS), was chosen over structural equation modeling (SEM), as 
SEM requires a larger sample size than I could obtain and requires more assumptions. 
Additionally, in regression analysis there is a clear difference between the independent 
and dependent variable, whereas with SEM these distinctions are applied in relative terms 
(Gunzler, Chen, Wu, & Zhang, 2013). The mediation model is a causal system where a 
predictor influences the outcome through one intervening variable (Hayes, 2013). The 
research model below shows the hypotheses that illness intrusiveness mediates the 
relationship between the IVIG treatment experience and QOL and that control mediates 
illness intrusiveness and QOL. 
 
Figure 2. The research model. IVIG = intravenous immunoglobulin; II = illness 
intrusiveness; QOL = quality of life as measured with 10 scales; control = 
multidimensional health locus of control 
IVIG 
Impact 
QOL 
10  
subscales 
II 
 
Control 
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Methodology 
Population 
The target population was neurological autoimmune disease patients, between the 
ages of 18 and 80 with diagnosis of MS, MMN, MG, or CIDP. Although these patients 
have different diagnoses they incur the same type of treatment, namely IVIG. The PNA 
assisted me in acquiring the required sample size according to the power analysis. 
Sampling and Sampling Procedures 
The sampling strategy was a convenience/nonrandom sample. While all potential 
participants meeting the criteria for inclusion in the study at PNA were contacted, it is 
always possible with convenience sampling that the sample is not representative of the 
entire population of MS, MMN, MG, and CIDP receiving IVIG as this is one of the 
disadvantages of this time sampling strategy (Trochim, 2006). External validity may have 
been threatened since it concerns the potential of generalizing the results of a study, 
which I was not be able to do only drawing participants from one infusion center 
(Trochim, 2006). The source for the accessible population for my study was invited to 
participate from one venue, PNA, located in Phoenix, AZ. PNA assisted in attaining the 
required sample size for this study. PNA is a neurology center with six experienced 
neurologists specializing in treatment and research involving many neurological diseases. 
For example, many of the neurologists are highly recognized in the treatment and 
research communities for their innovative practices such as the neuropathy clinic at 
Banner Good Samaritan Hospital in Phoenix, AZ. The infusion center within PNA gives 
infusions of IVIG to a variety of patients with neurological conditions. For the purposes 
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of this study only those with the diagnoses of MS, MMN, MG, and CIDP were invited to 
participate.  
An a priori power analysis was calculated (Faul, Erdfelder, Buchner, & Lang, 
2009) in order to estimate sample size. The original power analysis called for a sample 
size of 166 based on a Gpower of .09 for medium effect, .80 power, and .008 for 
probability based on Bonferonni with two predictors. However, given that only 79 
surveys were returned to me, I performed a post hoc analysis with Gpower for each of the 
9 QOL subscales which showed mediation during data analysis. I input the R² from the 
multiple linear regression, sample size of 79, two predictors, and probability .005 in 
Gpower then calculated the F² effect size followed by the estimation of power. Post hoc 
power analyses were reported with each mediation analysis. The effect sizes and the 
indirect effect are quantified in the analysis which follows. Kenny (2014) suggested two 
possible ways of determining medium effect size, either using the usual Cohen (1988) 
medium effect size of .3 or preferably squaring that to a medium effect of .09 since the 
indirect effect in a mediation is the product of the two different effects. Kappa-squared 
(k²) were reported for effect size in the mediation analysis as it is also one of the effect 
sizes automatically calculated in PROCESS. The effect size, k², describes the size of the 
indirect effect in relation to the maximum possible of the indirect effect given the design 
and data (Preacher & Kelley, 2011). Kappa-squared is interpreted the same as Cohen’s d 
(1988) with reference to small (.01), medium (.09), and large (.25) effect sizes. There are 
benefits to reporting k² as it is independent of sample size, is interpretable on a 0 to 1 
metric and is agreeable to creation of confidence intervals (Preacher & Kelly, 2011).  
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Recruitment 
Letters of explanation regarding the research study along with consent forms were 
distributed in sealed envelopes to the willing participants by the nursing director and the 
research coordinator for the infusion center. A meeting was held in May 2014 with the 
staff and me discussing the specifics of this distribution who were very interested as well 
as informed of ethical considerations. Inclusion criteria were specified as patients 
receiving IVIG treatment with one of the neurological autoimmune diseases MS, MMN, 
MG, or CIDP between the ages of 18 to 80 with the ability to read English. Exclusion 
criteria included any patients receiving IVIG who have a different medical diagnosis than 
those four being studied or are out of the age range 18 to 80. All patients meeting the 
inclusion criteria were invited to participate.  
Demographic information collected included gender, age, marital status, 
diagnosis, length of time with the particular diagnosis, length of time receiving IVIG 
treatment, and employment. Since interruption in life activities can occur from the first 
IVIG treatment, it was not necessary to delineate a certain length of time a person had 
been receiving treatment in order to be eligible for the study. As patients came into the 
infusion center for their IVIG they were informed about the nature of the research study 
explaining that was being conducted by a Ph.D. candidate at Walden University. If they 
were interested in participating they were given a sealed envelope with a letter explaining 
the study and a consent form. If the patient chose to participate they were given the 
envelope with the consent form and the questionnaire, which they completed, sealed, and 
mailed back in the provided envelope or gave them back to the nursing director. They 
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were kept separately locked until mailed to me. Since people were invited as they came 
into the center it was possible it could have taken as long as 3 months to collect the data 
depending on the patient's length between infusions.  
Participation 
Consent forms were distributed to ensure appropriate ethical standards for patient 
privacy as well as patients understanding the study was of a volunteer nature. If a patient 
made the voluntary decision to participate in the study the IVIG Impact Questionnaire, 
Neuro-QOL questionnaire, the IIRS questionnaire, and the MHLC were administered as 
the patients come to the clinic for IVIG infusions. Participation was voluntary. 
Data Collection 
Since the total completion time for questionnaires was approximately 30 minutes, 
patients had ample time to complete them during their infusion. The director of nurses 
stated she did not believe that was a problem for any of the patients at the center. Patients 
had the privacy of their own infusion space to complete the questionnaires, and were 
provided a sealed envelope in which to place the completed response.  
Instrumentation 
IVIG Experience Visual Analog Scale. The single-item VAS measured the 
IVIG experience and was presented as a 10-cm horizontal line with each end anchor 
distinctly marked. Patients were asked to mark the point on the line representing how 
they feel about their overall IVIG treatment experience. The single-item VAS measure 
uses a horizontal scale from 1 to 10. The distance from one end of the line to the patient's 
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mark was measured and afforded a quantitative variable. This was used for quantitative 
analysis.  
The single item VAS measure which I developed was presented as follows:  
Think about your experience with IVIG treatment which includes symptom relief, 
side effects, financial cost, changes from usual activities, improved health, 
adjusting schedules or family events, and improved mobility and place a mark on 
the line where you think it best represents what your experience has been overall. 
Anchors: 
As bad as it can be . …………………………………………..As good as it can be 
I used a single-item question in a VAS to measure the IVIG treatment experience 
which allowed the patient the opportunity to evaluate their total experience. Single-item 
VAS have demonstrated good reliability and validity in assessing QOL (de Boer et al., 
2004). Medical experts were consulted and agreed this would be the best plan (C. Gooch, 
K. Clarke, & S. McBride, personal communications, December, 2013 through May 
2014). The single-item question is included in the project questionnaire. Use of single-
item questions for predictive purposes has been discussed in more detail in Chapter 2.  
Illness Intrusiveness Rating Scale (IIRS). The IIRS measures illness 
intrusiveness in the following domains: health, active and passive recreation, diet, 
financial situation, work, relationship with partner, sex life, other social relations, family 
relations, self-improvement/self-expression, community and civic involvements, and 
religious expression. This was appropriate for the current study because the IVIG 
treatment experience was hypothesized to affect those potential domains in the patient's 
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life. The self-administered IIRS required respondents to rate the interference by the 
chronic disease on the central life domains.  
The scale has 13 items and uses a 7-point Likert scale, ranging from 1 (not very 
much) to 7 (very much). The items ask individuals to rate the level of life interference 
attributed to their disease and/or treatment for health, diet, work, active recreation, 
passive recreation, financial situation, relationship with your spouse, sex life, family 
relations, other social relations, self-expression/self-improvement, religious expression, 
and community and civic involvement. If a patient does not believe an item to be relevant 
a score of "1" indicates disease and/or treatment do not significantly interfere with that 
life domain. Higher scores mean patients are experiencing a higher level of intrusiveness 
(Devins, 2010). One question was erroneously omitted from the IIRS; therefore, findings 
reflect answers to only 12 of the 13 questions.  
The ratings are summed for responses to the 13 individual items in order to create 
a total score ranging from 13 to 91 (Devins, 2010). Internal consistency ranges from .80 
to .90 for 36 different chronic disease groups with the exception of one group (prostate 
cancer) which was .78. Construct validity has been good across chronic diseases. Devins 
(2010) stated that evidence for strong validity with the IIRS is shown by contrasting 
groups actually showing different IIRS scores. An example would be end-stage renal 
disease patients (who need frequent treatments and special diets) showing higher IIRS 
scores compared to transplant patients (who require a less rigorous treatment schedule) 
demonstrating lower IIRS scores (Devins, 2010). Discriminant validity is reinforced by 
results showing negative correlation between total IIRS scores and personal control 
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measures (Devins, 2010). Question 13 (the final question) was inadvertently omitted 
from the IIRS questionnaire. This question asks the patient how much their treatment 
interferes with their civic involvement. Permission to use the IIRS was granted by G.M. 
Devins, author of the scale through personal communication. 
Neuro-QOL. The Neuro-QOL instruments were developed as part of a NINDS 
research 6-year initiative (2004 to 2010) to develop psychometrically sound QOL 
measurements for neurological patients. The Neuro-QOL instrument is appropriate for 
individuals with common neurological disorders to determine health-related quality of 
life (Gershon et al., 2012; Nowinski, Victorson, Cacazos, Gershon, & Cella, 2010). The 
Neuro-QOL is a short self-assessment with 13 subscales (which the developers call item 
banks) that evaluate neurological patient issues, concerns, and symptoms and one stand-
alone scale which measures communication (Gershon et al., 2012). Since the Neuro-QOL 
system contains measures assessing similar issues in the majority of neurological diseases 
cross-disease comparisons are possible (Norwinski et al., 2010). Item banks are based on 
the individual's responses concerning the past 7 days such as "In the past 7 days... I felt 
depressed or I felt hopeless." Responses consist of five possibilities: never, rarely, 
sometimes, often, and always.  
As previously stated, the Neuro-QOL consists of one scale along with the 13 item 
banks. The one communication scale asks the individual to rate the difficulty they are 
having with writing, understanding communication, etc. The instrument demonstrated 
strong internal consistency (Chronbach α) ranging from 0.85 to 0.97 on the adult short 
forms (Cella et al., 2012) which was used in the current study. Scoring the short forms 
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consist of item responses being given a value (e.g., 1=Never, 2 = Rarely, 3 = Sometimes, 
4 = Often, 5 = Always). The sum of the response values for each question will create the 
raw score (NINDS, 2015). As an example, there are eight questions in a particular item 
bank form with a potential of five responses for each question where the lowest and 
highest raw scores would be 8 and 40 (NINDS, 2015). Higher Neuro-QOL scores mean 
more of the concept being measured (NINDS, 2015) 
The present study examined three areas of QOL health: physical, mental, and 
social. For physical health, functional health was assessed. For mental health, emotional 
and cognitive health was assessed. For social health, satisfaction with social roles and 
activities and the ability to participate in activities was assessed. Three item banks 
comprised functional health: upper extremity function, lower extremity function, and 
fatigue. Both upper and lower extremity function may be involved in neurological 
autoimmune diseases. Emotional health consisted of four item banks: depression, stigma, 
positive affect and well-being and emotional and behavioral dyscontrol. Cognitive health 
included applied cognition-general concerns, and applied cognition- executive. Finally, 
social health QOL incorporated satisfaction with social roles and activities, and ability to 
participate in social roles and activities (NINDS, 2015). The Neuro-QOL can be 
administered on-line or in paper format. Permission to use this instrument was granted by 
Northwestern University. 
Scoring the Neuro-QOL, which is the instrument measuring the dependent or 
outcome variable, was achieved by computing one total score for the each of the Neuro-
QOL subscales. These raw scores were computed by adding the total responses for each 
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subscale. For example, a subscale with eight questions and five possible responses would 
have a total raw score of 8-40. To accomplish this total score each of the 10 item banks 
were totaled in SPSS. The Neuro-QOL reports more of the concept being measured so 
subscales that are positive such as ability top in social activities would mean more of that 
ability and negatively worded subscales such as fatigue would reflect worse or less ability 
with a higher score (NINDS, 2015). 
Multidimensional Health Locus of Control (MHLC). The MHLC originated by 
Wallston, Wallston, and Devellis (1978), assesses individuals’ beliefs in their ability to 
personally control the health related factors in their disease and/or treatment. Form C of 
the MHLC was utilized for this study which was originally designed as a condition-
specific scale which can be adapted with patients who have existing medical diseases 
(Wallston et al., 1994). This study substituted the words "neurological autoimmune 
disease" for the word "condition" as was intended at the time of development of Form C 
in order to specify the medical problem of the participant population. Form C contains 18 
items. Two subscales, internal and chance contain six items each, and two independent 
subscales referred to as "doctors" and "other people" which contain three items in each 
(Wallston, 2007).  
Form C from the MHLC was used in its entirety, 18 items. This form asked 
patients to consider their beliefs about their medical condition or disease, if they agreed 
or disagreed with the statement on the scale. The MHLC uses a 6-point Likert-type scale 
with answers ranging from (1) strongly disagree to (6) strongly agree (Wallston, 2007). 
An example of an item from the internal subscale of the MHLC form C states, "If my 
83 
 
condition worsens, it is my own behavior which determines how soon I will feel better 
again." An example representing the concept of control by chance states, "As to my 
condition, what will be will be."  Sufficient internal consistency was demonstrated by the 
alpha reliabilities of α = .71 to α = .87 on the Form C subscales (Wallston et al., 1994). 
Discriminant and convergent validity were supported by significant correlations with 
corresponding items on subscales from Form B while conversely not correlating with 
non-corresponding items on Form B (Wallston et al., 1994). The subscales on Form C 
showed significant correlation with criteria which provided additional support for Form C 
validity (Wallston et al., 1994). Scoring Form C was accomplished by computing the sum 
of the values identified for each item (values 1 to 6), thus there was a potential score 
ranging from 18 to 108. Higher scores reflect more of the control being measured. The 
MHLC is a public domain instrument (Wallston, 2007). 
Data Analysis Plan 
The latest version of the Statistical Product and Service Solutions (SPSS) Package 
21 was used for the statistical analysis. I used this statistical program to assist me in 
keeping track of my data as it came in to me which is an important first step in logging in 
data. The data was screened for accuracy and completeness, and stored in an SPSS file 
(Trochim, 2006). A codebook was generated which included variable names, description, 
format, instrument, method of collection variable location, respondent, and notes 
(Trochim, 2006). 
Examination of each variable’s distributional properties and extreme scores or 
outliers was examined to reduce threats to validity and problems with Type I and Type II 
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errors. Following the suggestions of Osborne (2010) in the case of extreme scores they 
were corrected, truncated, removed, reduced in importance, or data transformed. When 
extreme scores are removed inferential statistics and correlations show a lower rate of 
error (Osborne, & Overbay, 2004). The outlier labeling method was utilized to check for 
extreme scores. There were no outliers in the data. 
 The Neuro-QOL was analyzed in 10 separate scales for the dependent variable. It 
was imperative to score each Neuro-QOL subscale independently rather that computing 
one total score as each scale measures a different and independent physical, emotional or 
social domain and they are always scored independently. Bonferroni was used since the 
scales are being analyzed separately. 
Mediation is a causal system (Hayes, 2013). It is proposed that one antecedent (X) 
influences an outcome (Y) by way of a single intervening variable (M). The pathways 
include the path leading from X to Y without passing through M which is referred to as 
the direct effect of X on Y and another pathway referred to as the indirect effect which is 
the path from X to Y through M. Earlier approaches recommended that mediation should 
only be undertaken when an association is demonstrated between X and Y (Baron & 
Kenny, 1986). It is no longer advocated by most scholars of mediation analysis in 
methodology literature (Hayes, 2013). In fact, many quantitative methodologists have 
agreed that the total effect of X on Y should not be required as a pre-condition prior to 
investigating indirect effects (Cerin & MacKinnon, 2009; Hayes, 2009; MacKinnon, 
2008; Rucker et al., 2011; Shrout & Bolger, 2002; Zhao et al., 2010).  
The research questions and hypotheses were as follows: 
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RQ1: Is the IVIG treatment experience (as measured by the VAS) a 
significant predictor of QOL in patients with autoimmune disorders who receive 
IVIG treatment as measured by 10 separate QOL scales?  
H11: The IVIG treatment experience (as measured by the VAS) is a 
significant predictor of QOL as measured by 10 separate scales in patients with 
MS, MMN, MG, and CIDP who receive IVIG treatment.  
H01: The IVIG treatment experience (as measured by the VAS) is not a 
significant predictor of QOL as measured by 10 separate scales in patients with 
MS, MMN, MG, and CIDP who receive IVIG treatment.   
RQ2: Does illness intrusiveness mediate the relationship between the 
IVIG treatment experience and QOL (as measured by 10 separate scales of the 
Neuro-QOL) among individuals with autoimmune disease who received IVIG 
treatment? 
H12:  Illness intrusiveness mediates the relationship between the IVIG 
treatment experience and QOL (as measured by 10 separate scales of the Neuro-
QOL) among individuals with MS, MMN, MG, and CIDP. 
H02: Illness intrusiveness does not mediate the relationship between the 
IVIG treatment experience and QOL (as measured by 10 separate scales of the 
Neuro-QOL) among individuals with MS, MMN, MG, and CIDP). 
RQ3: Does personal control mediate the relationship between Illness 
Intrusiveness and QOL as measured by 10 separate scales among individuals with 
autoimmune disease who receive IVIG treatment? 
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H13: Personal control does mediate the relationship between illness 
intrusiveness and QOL as measured by s 10 separate scales among individuals 
with MS, MMN, MG, and CIDP. 
H03: Personal control does not mediate the relationship between illness 
intrusiveness and QOL as measured by 10 separate scales among individuals with 
MS, MMN, MG, and CIDP. 
Demographic data were examined during the first phase of data analysis, and 
descriptive statistics are reported in Chapter 4. Then the predictor and outcome variables 
were examined, and descriptive statistics and exploratory analyses were conducted and 
reported. These exploratory analyses determined if the data met the assumptions for the 
regression and mediation analyses (Trochim, 2006; Kenny, 2014) 
Mediation occurs when a predictor variable, relates to a dependent variable 
through a mediator and can be tested statistically. The direct path leads from predictor to 
the dependent variable without passing through the mediator and the indirect path travels 
from the predictor variable to the dependent variable through the mediator (Hayes, 2009, 
2013; Kenny, 2014). Current research indicates verification of a simple association 
between the predictor variable and the dependent is not a prerequisite in mediation 
analysis (Cerin & MacKinnon, 2009; Hayes, 2013; Preacher & Kelly, 2011; Shrout & 
Bolger, 2002; Zhao et al., 2010). Therefore, Process Macro for SPSS (version 2.13) was 
used for the mediation analysis in this dissertation. PROCESS uses OLS regression for 
path analysis-based mediation analysis which estimates unstandardized model 
coefficients, t and p values, standard errors, confidence intervals as well as generating 
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direct and indirect effects and bias-corrected and percentile bootstrap confidence intervals 
and various effect sizes (Hayes, 2013). Model 4 in PROCESS was used which is 
designed for mediation models computing the indirect and direct effects. 
Threats to Validity 
The current study was a nonexperimental correlational, cross-sectional study, 
drawing participants from one IVIG clinic in the United States. The use of nonrandom 
sampling of treatment sites and study participants means the results of the study may not 
be generalizable to the population of patients receiving IVIG treatment. Further, selection 
bias might plausibly be a problem in the study as the participants will “opt-in” to create 
the convenience sample and are not randomly selected (Trochim, 2006). Bootstrapping 
methods was used to assess potential sample representativeness (Kenny, 2014). 
Regarding internal validity, the nature of cross-sectional survey research design 
precludes the use of control or comparison groups, and the use of repeated measures. 
Therefore, internal validity is weak, as I had little control over who chooses to participate 
or the research conditions. Therefore, issues like maturation and history are not relevant 
(Willson & Putnam, 1982). To maximize internal validity, I selected measures with 
acceptable psychometric properties. Statistical conclusion validity was supported by 
exploring the data sufficiently to understand its distributional properties and employ 
appropriate statistical techniques using the conventional probability of .05 statistical 
significance level in order to avoid Type I error (Petrocelli, 2003).  
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Ethical Procedures 
PNA of Phoenix, Arizona gave permission for access to the patients receiving 
IVIG for the purposes of this project. If patients agreed to participate in this research 
study they were given an envelope containing the self-reporting questionnaires previously 
mentioned in this chapter. Recruitment was voluntary as patients entered the infusion 
center to receive IVIG. If patients did not desire to participate they were not given the 
questionnaires. The patient could opt out of the study at any time. Patients at all times 
maintained control over their participation in the study. Questionnaires did not contain 
names or personal identification. Upon completion of the surveys they were remitted to 
me and remained under the sole care of me protected in a locked file box. Personal data 
was secured separately from research data and both will be password-protected. 
Data from this research study will be disseminated in several ways. Dr. Gerald 
Devins has requested I consider sharing the raw IIRS item responses and relevant clinical 
data (e.g., medical and background information) with him for the purposes of 
accumulating norms and psychometric refinement of the instrument when he gave 
permission for the use of the IIRS in this quantitative study. The data results may also be 
shared with the medical staff of the PNA in Phoenix, AZ or potentially with IVIG nurses 
for educational purposes. Participants were notified of this in the Informed Consent 
Agreement. Permission to collect data was obtained from Walden University Internal 
Review Board ([IRB] approval # 01-13-15-0192064). 
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Summary 
Chapter 3 explained the methodology for this quantitative nonexperimental 
research designed study. The purpose of the study was to examine the relationship 
between the IVIG experience and QOL in neurological autoimmune patients. The 
quantitative nonexperimental research study was based on the relevant constructs of the 
illness intrusiveness theory and personal control theory to assess the mediating influence 
of illness intrusiveness on the relationship between the IVIG experience and QOL as well 
as the possible mediating effects of personal control on the relationship between IVIG 
experience and QOL. Data was obtained through convenience sampling of neurological 
autoimmune patients receiving IVIG treatment at PNA in Phoenix, AZ. The following 
questionnaires were employed to collect data: IIRS to assess illness intrusiveness, Neuro-
QOL to measure quality of life, MHLC-Form C to measure personal control, and a 
single-item VAS to measure the IVIG experience. Multiple regression was utilized to 
assess the mediation and predictive relationships. Precautions were used to assure privacy 
of all data. Chapter 4 presents the results and discussion of data collected. 
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Chapter 4: Results  
Introduction 
The purpose of the research was to examine the relationship between the IVIG 
treatment experience (predictor variable) and QOL (outcome variable) in neurological 
autoimmune patients. Responses from a project questionnaire were gathered from 
patients receiving IVIG treatment at PNA, an infusion center in Phoenix, AZ. Analysis 
was performed to ascertain the following: (a) whether the IVIG treatment experienced 
was a significant predictor of QOL in patients with autoimmune disease, (b) if illness 
intrusiveness mediated the relationship between the IVIG treatment experience and QOL, 
and (c) did personal control mediate the relationship between Illness Intrusiveness and 
QOL among individuals with autoimmune disease who receive IVIG treatment. 
Data Collection 
The data for this research study were collected using surveys distributed to 
interested patients at the PNA infusion center in Phoenix, AZ who were receiving IVIG 
treatment for neurological autoimmune disorders. Data collection began in January 2015 
and ended in June 2015. Participants were offered the opportunity to participate in the 
study as they entered the IVIG infusion center, and if they chose to participate, could 
either fill out the questionnaires at the center and the nursing staff returned them to me by 
mail or the patient could return them on their own in the mail. A total of 79 patients 
responded by mailing their surveys back to me. The data collection site thought there 
would be access to more patients when the data collection process was originally begun. 
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Participants provided demographic information which included gender, age, 
employment status, diagnoses, length of time diagnosed, how often they receive IVIG 
treatment, length of time the administration of IVIG lasts, whether they receive 
premedication, and whether they experience side effects after IVIG treatment. Data were 
entered into SPSS 21. Total scores were calculated per SPSS computation directions. 
Descriptive Statistics 
The study included 25 male (31.6%) and 54 female (68.4%) participants who 
ranged in age from 18 to 80 with the largest percent (26.6%) being 60 to 70 and the 
second largest percent (25.3%) in the 50 to 60 age group. The IVIG patient group 
consisted of 37 (46.8%) employed or self-employed and 41 (51.9%) unemployed. All 
four diagnoses were represented with 30 MS, 25 CIDP, 13 MG, and 11 MMN patients. 
Patients had been diagnosed with a neurological autoimmune disease from 3 months (.25) 
to 44 years with a mean of 8.76 (SD = 7.97) years. The largest percentage of patients, 
43% received IVIG every 4 to 5 weeks and 92.4% receive infusions over a 4 to 5 hour 
time period. Premedication prior to IVIG is given to 83.5% of the participants with 
51.9% reporting side effects some of the time. This was not a random sample, so 
generalizability of the findings cannot be assumed. However, other infusion centers have 
populations similar to PNA, with a large percentage of their patients diagnosed with MS, 
MMN, MG, and CIDP (PNA, 2015). All four of these disease populations are 
underreported so it becomes difficult to speculate on an exact population number and 
comparison (Laughlin et al., 2009; Lawson & Arnold, 2014). This infusion center’s 
medical staff indicated their population is similar to other IVIG infusion centers, so it is 
92 
 
reasonable to suggest that the current sample is likely typical of the population receiving 
IVIG at infusion centers. Table 1 displays demographics of the study participants. 
Table 1 
Descriptive Demographics of Study Participants 
 Frequency Percent 
Gender   
Male 25 31.6 
Female 54 68.4 
Age   
18 - 30 3 3.8 
31 - 40 13 16.5 
41 - 50 13 16.5 
51 - 60 20 25.3 
61 - 70 21 26.6 
71 - 80 9 11.4 
Employment   
Not Employed 41 51.9 
Employed or Self-
Employed 
37 46.8 
Diagnosis   
MS 30 38.0 
CIDP 25 31.6 
MG 13 16.5 
MMN 11 13.9 
IVIG Frequency   
2 weeks 13 16.5 
3 weeks 9 11.4 
4 – 5 weeks 34 43.0 
6 – 7 weeks 
8 weeks or more 
   
 
20 
3 
24.3 
   3.8 
 
 
         (table continues) 
 
                                                               
   
93 
 
 
 
  
 Frequency Percent 
 
 
Length of IVIG 
  
1 hour 1  1.3 
3 hours 5  6.3 
4 hours 35 44.3 
5 or more hours 38 48.1 
Pre-medication   
No 13 16.5 
Yes 66 83.5 
Side Effects   
Never 18 22.8 
Sometimes 41 51.9 
Most of the time 9 11.4 
Always 11 13.9 
 
Examination of Distributional Properties 
Outliers can differ from the main direction of the data and may influence the 
coefficients in regression (Field, 2013). The outlier labeling method was used in this 
study to determine if significant outliers were present. SPSS was used by taking the 
difference between the 25th (lower quartile) and 75th percentiles (upper quartile) 
multiplied by the standard factor 2.2 to define the presence of upper or lower outliers 
(Hoaglin & Iglewicz, 1987). Outliers for QOL total scores would have been 314.46 upper 
limit and 188.81 lower limit. There were no outliers in QOL total scores. 
Missing data were sparse but were analyzed and the Little’s Missing Completely 
at Random (MCAR) test was performed which was found to be nonsignificant at .879, 
which indicated missing values were missing completely at random. Missing data were 
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replaced using expectation maximization provided in the SPSS program. Expectation 
maximization is a missing value imputation strategy which estimates missing data from 
estimated parameters of observed data (Acock, 2005; Schlomer, Bauman, & Card, 2010). 
There was one VAS missing and 3 subscales missing, one quality of life lower extremity 
function (QOLLEF), one quality of life satisfaction with social roles and activities 
(QOLSSRA), and one quality of life depression (QOLDEPR). VAS and QOLLEF were 
from different participants and QOLSSRA and QOLDEPR were from the same 
participant. Nothing was changed after these analyses. I left these subscales missing in 
the analysis. 
Examination of Multivariate Assumptions  
Normality testing was performed by SPSS. Skewness and kurtosis were examined 
in order to evaluate if they would influence the analysis. Skewness reflects the symmetry 
of values with 0 being a normal distribution (George & Mallery, 2011). A skewness of +1 
and -1 is acceptable. Kurtosis of +1 and -1 is viewed as excellent (George & Mallery, 
2011). Results are presented in Table 2. 
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Table 2 
Descriptive Statistics of Key Variables 
Variable N Mean SD Skewness Std. 
Error 
Kurtosis Std. 
Error 
    Statistic  Statistic  
VAS 78 76.17 19.71  -.724 .272 -.071 .538 
IIRS 79 41.41 16.07   .201 .271 -.892 .535 
HCS 79 58.62 10.23  -.076 .271  .092 .535 
SSRA 78 25.50  8.82  -.265 .272 -.819 .538 
FATIG 79 26.99  7.17  -.244 .271 -.448 .535 
DEPR 78 14.76  7.58  1.125 .272  .507 .538 
PAWB 79 35.67  7.14  -.798 .271  .312 .535 
STIG 79 14.49  6.23   1.03 .271  .498 .535 
COG 79 30.03  7.59  -.472 .271 -.709 .535 
SLP 79 20.30  6.99   .289 .271 -.983 .535 
EBD 79 17.14  6.18   .741 .271  .221 .535 
LEF 78 31.60  8.38  -.836 .272 -.446 .538 
UEF 79 36.34  4.87  -1.18 .271  .211 .525 
Note. VAS = Visual Analog Scale; IIRS = Illness Intrusiveness Rating Scale; HCS = Personal Control 
SSRA = Satisfaction with Social Roles and Activities; FATIG = Fatigue; DEPR = Depression; PAWB = 
Positive Affect and Well-Being; STIG = Stigma; COG = Cognition; SLP = Sleep; EBD = Emotional and 
Behavioral Dyscontrol; LEF = Lower Extremity Function; UEF = Upper Extremity Function. 
 
The assumption of homoscedasticity was assessed by viewing a scatterplot 
between residuals and predicted values. The plot showed no suggestion of a pattern and 
the assumption was met. The assumption of linearity was met as the scatterplots were 
uniform around a linear fit line. Below the correlation matrix is presented for the 
independent variables and the dependent variables of QOL. Correlation of predictor 
variables and Neuro-QOL outcome scales are displayed in Table 3. 
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Table 3 
Correlation of predictor variables and Neuro-QOL outcome scales 
 VAS IIRS HCS 
PAWB         .34** -.47** .13 
SSRA       .32* -.66** .03 
FATIG            -.29*  .61** .04 
DEPR       -.29*  .55** -.07 
COG            -.01 -.40** .10 
STIG            -.06  .50** .06 
SLP            -.10  .60** .06 
EBD            -.40  .43** .03 
LEF             .17 -.33** .08 
UEF             .16           -.09 .04 
Note. VAS = Visual Analog Scale; IIRS = Illness Intrusiveness Rating Scale; HCS = Personal Control; 
PAWB = Positive Affect and Well-Being; SSRA = Satisfaction with Social Roles and Activities; FATIG = 
Fatigue; DEPR = Depression; COG = Cognition; STIG = Stigma; SLP = Sleep; EBD = Emotional 
Behavior and Dyscontrol; LEF = Lower Extremity Function; UEF = Upper Extremity Function. 
*Correlation is significant at p < .01; ** Correlation is significant at p < .005 
Multicollinearity can occur when there is a strong association between predictor 
variables (Field, 2013). I used SPSS to perform collinearity statistics for each of the 
predictors for Hypotheses 2 and 3. Each variable, VAS, IIRS, and MHLC took a turn as 
the dependent variable. None of the variables were found to have high correlations with 
the other variable. The variance inflation factor (VIF) was 1.05, 1.004, and 1.001 
respectively. These values were below 3 which is considered to be a level of concern 
(Field, 2013; O’Brien, 2007). Tolerance values were .949, .996, and .999 respectively. 
These tolerance values do not fall below 0.2 which could indicate a multicollinearity 
problem (Field, 2013). Although SPSS produces multicollinearity statistics, the 
correlation matrix can also be scanned to see if any of the predictors are highly 
correlated. The scanning method may miss some more subtle signs of multicollinearity 
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according to Field (2013); however, the correlation matrix for the current study revealed 
no problems in collinearity either as the predictor variables were not highly correlated.  
There were some interesting correlations between some of the dependent variables 
(Neuro-QOL scales) which will be discussed in Chapter 5 as other noteworthy findings. 
Table 4 displays the correlations in the Neuro-QOL scales. 
Table 4 
Correlation of Neuro-QOL scales 
 PAWB SSRA FATI DEPR COG STIG SLP EBD LEF UEF 
PAWB 1 .50*** -.45*** -.72*** .32** -.41*** -.44*** -.36*** .26* .35** 
SSRA  1 .73*** -.64*** .34*** -.56*** -.56*** -.36*** .58*** .35*** 
FATI   1 .58*** -.52*** .44*** .68*** .37*** -.37*** -.28* 
DEPR    1 -.42*** .66*** .59*** .43*** -.37*** .40*** 
COG     1 -.29** -.50*** -.26* .16 .16 
STIG      1 .55*** .45*** -.47*** -.39*** 
SLP       1 .53*** -.42*** -.31** 
EBD        1 -.04 -.09 
LEF         1   .52*** 
UEF          1 
Note. PAWB = Positive Affect and Well-Being; SSRA = Satisfaction with Social Roles and Activities; 
FATI = Fatigue; DEPR = Depression; Cog = Cognition; STIG = Stigma; SLP = Sleep; EBD = Emotional 
and Behavioral Dyscontrol; LEF = Lower Extremity Function; UEF = Upper Extremity Function. 
*** Correlation at p < .005; ** Correlation at p < .01; * Correlation at p < .05 
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Results 
Research Question 1 
RQ1: Is the IVIG treatment experience (as measured by the VAS) a significant 
predictor of QOL as measured by the 10 Neuro-QOL scales in patients with autoimmune 
disorders who receive IVIG treatment?  
Research Question 1 was answered by performing a Pearson’s correlation analysis 
and regression with the test of path c in the mediational analysis. I conducted a 
correlational analysis to examine the associations between IVIG treatment experience 
(VAS) and the Neuro-QOL separate scales. Bonferroni correction was employed due to 
the testing of the 10 Neuro-QOL scales separately. Bonferroni may protect from Type I 
error at the risk of Type II error (Field, 2013). In this case Bonferroni meant the 
significance value would be p < .005. The predictor IVIG treatment experience as 
measured by the VAS showed a significant correlation (<.005) with the Neuro-QOL 
scale, positive affect and well-being. The results of the simple linear regression for the 
Neuro-QOL positive affect and well-being was significant (R² = .12). The other nine 
Neuro-QOL scales were not statistically significant at alpha .005. The Null Hypothesis 1 
was rejected for the Neuro-QOL scale, positive affect and well-being. However, I failed 
to reject the null hypotheses for the other nine Neuro-QOL scales. Correlations for IVIG 
treatment experience and the Neuro-QOL scales are presented in Table 3.Although IVIG 
treatment experience (VAS) did not significantly predict QOL in the remaining nine QOL 
subscales, recent literature supports that mediation analysis does not require verification 
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of the simple association between X and Y to be able to test hypotheses regarding 
indirect effects, thus all ten QOL dependent variables were tested for indirect effects 
(Hayes, 2009, 2013; Rucker et al., 2011; Zhao et al., 2010). 
Research Question 2 
RQ2: Does illness intrusiveness mediate the relationship between the IVIG 
treatment experience and QOL (as measured by the 10 Neuro-QOL scales) among 
individuals with autoimmune disease who received IVIG treatment? 
I performed a mediation analysis on all 10 of the Neuro-QOL subscales including 
those subscales that did not show a correlation between X and Y with Process Macro 
version 2.13. I used the robust test of bootstrap confidence intervals (a repeated sampling 
of the population) for estimating the indirect effect which makes no assumption about the 
distribution shape of ab. In fact, bootstrapping has been demonstrated to yield higher 
power when testing a hypothesis (Hayes, 2013).  
Nine of the 10 QOL subscales revealed an indirect effect (Rucker et al., 2011) 
which are demonstrated in the tables of the statistical indices for each mediation and the 
path diagrams which follow. I rejected the null hypotheses in those nine QOL subscales. 
Unstandardized coefficients are reported as they are the preferred metric in causal 
modeling and results can be compared directly with studies performed utilizing the same 
measurement system (Hayes, 2013). VAS was the independent variable, IIRS was the 
mediator, and each of the Neuro- QOL variables were tested in a separate mediation 
analysis. 
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QOL Satisfaction with Social Roles and Activities 
The first mediation analysis examined whether Illness Intrusiveness mediates the 
relationship between IVIG treatment experience and QOL in social roles and activities. 
The multiple regression was significant, R² = .461, F(2, 74) = 31.68, p ˂ .001. The results 
indicate that 46% of the variance in satisfaction with social roles and activities was 
predicted by IVIG treatment experience and illness intrusiveness. The unstandardized 
coefficients for paths a, b and cʹ respectively were b = -0.186, t(74) = -2.012, p = .048; b 
= -0.331, t(75) = -7.024, p ˂ .001; path cʹ = 0.080, t(75), = 2.06, p = .0429. The total 
effect, b = 0.141, t(75) = 2.92, p = .004  showed R² = .10 indicating IVIG treatment 
experience explained 10% of the variance in QOL but the larger portion of variance was 
illness intrusiveness.  
A bias-corrected bootstrap confidence interval for the indirect effect (ab = .061) 
based on 10,000 bootstrap samples was entirely above zero [0.0085, 0.1271] indicating 
mediation. The null hypothesis was rejected for the QOL satisfaction with social roles 
and activities subscale. A post hoc test using Gpower with a probability error of .005 and 
sample size of 79 revealed a power of .99. The effect size k² = .16 with 95% CI [0.0227, 
0.2888] was considered a medium effect (Preacher & Kelley, 2011). Figure 3 displays a 
statistical path diagram and Table 5 displays statistical indices of the result of the 
mediation of IVIG treatment experience (VAS) and QOL satisfaction with social roles 
and activities (QOLSSRA).  
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Table 5 
Mediation Model Coefficients for IVIG Treatment Experience and QOL Satisfaction with 
Social Roles and Activities 
     Outcomes    
  M (Illness Intrusiveness)  Y (QOLSSRA) 
Predictor Path b SE p Path b SE p 
IVIG 
(VAS) 
a -0.186 0.092 .047 c′ 0.080 0.039 .0429 
     b -0.331 0.047 < .001 
  R2 = .051 
F(1, 75) = 4.049, p = .048 
 R2 = .461 
F(2, 74) = 31.684, p < .001    
Note. IVIG = Intravenous Immunoglobulin; VAS = Visual Analog Scale; QOLSSRA = Quality of Life 
Satisfaction with Social Roles and Activities. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Model of IVIG treatment experience (VAS) and QOL satisfaction with social  
roles and activities mediated by illness intrusiveness.  
 
QOL Depression  
A multiple regression was performed to predict the variable Neuro-QOL 
Depression from IVIG treatment experience (VAS) and illness intrusiveness. The 
Illness  
Intrusiveness 
IVIG Treatment 
Experience (VAS) 
QOL Satisfaction with 
Social Roles and 
Activities 
a -0.186, p = .0478 
b = -0.331, p ˂ .001 
cʹ = 0.080, p = .042, Indirect effect, b 
= 0.061, 95 % CI [.0085, 0.1271] 
 
Illness Intrusiveness 
QOL Satisfaction with 
Social Roles and 
Activities c = 0.141, p = .004 
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regression was significant, R² = .328, F(2,74) = 18.085, p ˂ .001. The R² value of .33 
estimates that the model explains about 33% of the variance in QOL depression. Paths a, 
b, and c′ respectively were b = -0.1856, t (75) = 2.012, p = .048; b = 0.237, t (75) = 5.161, 
p ˂ .001, and b = -0.070, t (75) = -1.840, p = .0698. The total effect (path c) indicated 
VAS significantly predicts QOL depression even when illness intrusiveness is not in the 
model, b = -0.1131, t (75) = -2.666, p = .009.  
A bias-corrected bootstrap confidence interval based on 10,000 samples for the 
indirect effect (ab = -.044) did not include zero [-.1031, -.0069] indicating mediation. I 
rejected the null hypothesis for Neuro- QOL depression. A post hoc test using Gpower 
was calculated indicating a power of .96 for the sample size of 79. The effect size k² = .12 
with a 95% CI [0.0187, 0.2465] was medium. Statistical analyses in the form of a path 
diagram in Figure 4 and statistical indices displayed in Table 6 revealed there was 
significant mediation between illness intrusiveness and QOL depression. 
Table  6 
Mediation Model Coefficients for IVIG Treatment Experience and QOL Depression 
     Outcomes    
  M (Illness Intrusiveness)  Y (QOLDEPR) 
Predictor Path b SE p Path b SE p 
IVIG 
(VAS) 
a -0.186 0.092 .047 c′ -0.0692 0.0376 .0698 
     b 0.2366 0.0458 < .001 
  R2 = .05 
F(1, 75) = 4.049, p = .048 
 R2 = .33 
F(2, 74) = 18.0851, p < .001    
Note. IVIG = Intravenous Immunoglobulin; VAS = Visual Analog Scale; QOLDEPR = Quality of Life 
Depression. 
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    c = -0.113, p ˂ .01 
 
 
 
 
 
       a = -0.186, p = .048          b = 0.237, p ˂ .001  
          
 
          
 
 
Figure 4. Model of IVIG treatment experience and QOL depression, mediated by illness 
intrusiveness with unstandardized coefficients. 
 
QOL Fatigue 
A mediation analysis was conducted predicting illness intrusiveness from IVIG 
treatment experience as well as QOL fatigue from both IVIG treatment experience and 
illness intrusiveness. The multiple regression was significant, R² = .394, F(2,75) = 
24.327, p ˂ .001 indicating 39% of the variance in QOL fatigue was accounted for by 
IVIG treatment experience and illness intrusiveness. Paths a, b respectively were b = -
0.184, t(76) = -2.01, p = .048; b = 0.252, t(76) = 6.16, p ˂ .001. The direct effect (path c′) 
was negative, b = -0.060, t(76) = -1.79, p = .077. The total effect (path c) was negative, b 
= -0.106, t(76) = -2.68, p = .009.  
A bias-corrected bootstrap confidence interval for the negative indirect effect, b = 
-0.046 based on 10,000 samples did not include zero 95% CI [-0.096, -0.006] indicating 
Illness Intrusiveness QOL Depression 
Illness Intrusiveness 
IVIG Treatment 
Experience 
QOL 
Depression 
cʹ = -0.07, p = .070, 
Indirect effect, b = -.444, 95% CI 
[-0.1031, -0.0069] 
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mediation. I rejected the null hypothesis for the Neuro-QOL Fatigue scale. A post hoc 
test using Gpower was performed indicating a power of .98 for the sample of 79. The 
effect size, k² = .14 with a 95% CI [0.0202, 0.2553] was medium. Figure 5 provides the 
statistical figure for the mediation analysis and statistical indices are displayed in Table 7.  
Table  7 
Mediation Model Coefficients for IVIG Treatment Experience and QOL Fatigue 
     Outcomes    
  M (Illness Intrusiveness)  Y (QOLFATIG) 
Predictor Path  b SE p Path b SE p 
IVIG 
(VAS) 
a -.184 .092 .047 c′ -.060 .033 .077 
     b .252 .041 < .001 
  R2 = .05 
F(1, 75) = 4.049, p = .048 
 R2 = .394 
F(2, 75) = 24.327, p < .001    
Note. IVIG = Intravenous Immunoglobulin; VAS = Visual Analog Scale; QOLFATIG = Quality of Life 
Fatigue. 
 
 
 
 
 
 
 
 a = -0.184, p = .047          b = 0.252, p ˂ .001 
  
     
 
 
Figure 5. Model of IVIG treatment experience and QOL Fatigue mediated by illness 
intrusiveness with unstandardized coefficients. 
IVIG Treatment 
Experience 
QOL Fatigue 
Illness 
Intrusiveness 
IVIG Treatment 
Experience 
QOL Fatigue 
Direct effect, b = -.060, p = .077 
Indirect effect, b = -.046, 95% CI [-0.096, 
0.006] 
c = -0.106, p ˂ .009 
105 
 
 
QOL Positive Affect and Well-Being 
A mediation analysis was performed to predict QOL positive affect and well- 
being from IVIG treatment experience and illness intrusiveness. The regression was 
significant, R² = .273, F(2,75) = 14.06, p ˂ .001 indicating 27% of the variance in QOL 
positive affect and well-being was predicted by IVIG treatment experience and illness 
intrusiveness. Paths a and b respectively were b = -0.184, t(76) = -2.012, p = .047;  b = -
0.180, t(76) = -4.029, p ˂ .001. The direct effect (path cʹ) was positive, b = 0.089, t(76) = 
2.452, p = .017 and the total effect (path c) was positive and significant, b = 0.122, t(76) 
= 3.15, p = .002. 
A bias-corrected bootstrap confidence interval for the indirect effect (ab = .033) 
based on 10,000 bootstrap samples was entirely above zero 95% CI [0.0062, 0.0787] 
indicating mediation. I rejected the null hypothesis for the Neuro- QOL positive affect 
and well-being. A post hoc test using Gpower with a probability error of .005 showed a 
power of .91 for the sample of 79. The effect size k² = .10 with 95% CI [0.0184, 0.1998] 
was medium. Mediation is illustrated by the path diagram in Figure 6. The statistical 
indices displayed in Table 6 indicated there was a significant indirect effect. 
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Table  8 
Mediation Model Coefficients for IVIG Treatment Experience and QOL Positive Affect 
and Well-Being 
     Outcomes    
  M (Illness Intrusiveness)  Y (QOLPAWB) 
Predictor Path  b SE p Path b SE p 
IVIG 
(VAS) 
a -0.184 0.091 .048 c′ 0.089 0.036 .017 
     b -0.180 0.045 < .001 
  R2 = .05 
F(1, 76) = 4.049, p = .048 
 R2 = .273 
F(2, 75) = 14.057, p < .001    
Note. IVIG = Intravenous Immunoglobulin; VAS = Visual Analog Scale; QOLPAWB = Quality of Life 
Positive Affect and Well-Being. 
 
 
 
     
     
 
 
 
 
 
 
             a = -0.183, p = .048      b = -0.180, p ˂ .001 
 
 
 
 
 
 
 
Figure 6. Model of the relationship between IVIG treatment experience and QOL 
positive affect and well-being mediated by illness intrusiveness. 
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IVIG Treatment 
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c = 0.122, p = .002 
Direct effect, b = 0.089, p = .02 
Indirect effect, b = .033, 95% CI [.0062, 
.0787] 
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QOL Sleep 
A mediation analysis was conducted to predict QOL sleep from IVIG treatment 
experience and illness intrusiveness. The multiple regression was significant, R² = .36, 
F(2, 75) = 20.634, p ˂ .001 indicating the model explained 36% of the variance in QOL 
Sleep. Paths a and b respectively were b = -0.184, t(76) = -2.012, p = .048; b = 0.259, 
t(76) = 6.34, p ˂.001. The direct effect was not significant, (cʹ), b = 0.013, t(76) = .397, p 
= .692. The total effect (path c) was not significant, b = -0.034, t(76) = -0.857, p = .394. 
A percentile bootstrap confidence interval for the indirect effect (ab = -.048) based on 
10,000 bootstrap samples did not include zero 95% CI [-.1017 to -.0057] indicating 
mediation. I rejected the null hypothesis for the Neuro- QOL Sleep scale. I conducted a 
post hoc test using Gpower with a probability error of .005 which showed .97 power for 
the sample size of 79. The effect size, k² = .16 with 95% CI [0.0257, 0.3126] was 
medium. Statistical indices are displayed in Table 9 and a statistical diagram of the 
mediation model is displayed in figure 8. 
Table  9 
Mediation Model Coefficients for IVIG Treatment Experience and QOL Sleep 
     Outcomes    
  M (Illness Intrusiveness)  Y (QOLSLP) 
Predictor Path  b SE p Path b SE p 
IVIG 
(VAS) 
a -0.184 0.091 .048 c′ 0.013 0.033 .692 
     b 0.259 0.041 < .001 
  R2 = .05 
F(1, 76) = 4.049, p = .048 
 R2 = .36 
F(2, 75) = 20.6347, p < .001    
Note. IVIG = Intravenous Immunoglobulin; VAS = Visual Analog Scale; QOLSLP = Quality of Life 
Sleep. 
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Figure 7. Model of the relationship between IVIG treatment experience and QOL sleep 
mediated by illness intrusiveness. 
 
QOL Stigma 
A mediation analysis was conducted to assess the relationship of IVIG treatment 
experience on QOL stigma through illness intrusiveness. The multiple regression was 
significant. R² =.249, F(2, 75) = 12.472, p ˂ .001 indicating 25% of the variance in QOL 
stigma was explained by IVIG treatment experience and illness intrusiveness. Path a was 
negative, b = -0.184, t(76) = -2.012, p = .048 and path b was significant and positive , b = 
0.197, t(76) = 4.962, p ˂ .001. The direct effect was not significant (path cʹ), b = .018, 
t(76) = .566, p = .573. The total effect (path c) was not significant, b = -0.018, t(76) = -
.493, p = .623. However, a bias-corrected bootstrap confidence interval of 10,000 
samples for the indirect effect (ab = -.036) did not include zero 95% CI [-.0841 and -
IVIG Treatment  
Experience 
QOL Sleep 
c = -0.034, p = .394 
Illness  
Intrusiveness 
IVIG Treatment 
Experience 
 
QOL Sleep 
a = -0.184, p = .048 b = 0.259, p ˂ .001 
Direct effect, b = 0.013, p = .692 
Indirect effect, b = -0.048, 95% CI  
[-0.1017, -0.0057] 
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.0052] indicating mediation. I rejected the null hypothesis for QOL stigma. A post hoc 
power analysis with Gpower with probability error set at .005 indicated a power of .88. 
The effect size of k² = .13 with 95% CI [0.0189, 0.2853] was medium. Statistical indices 
are provided in Table 10 and the statistical diagram of mediation is displayed in Figure 8. 
Table  10 
Mediation Model Coefficients for IVIG Treatment Experience and QOL Stigma 
     Outcomes    
  M (Illness Intrusiveness)  Y (QOLSTIG) 
Predictor Path  b SE p Path b SE p 
IVIG 
(VAS) 
a -0.184 .091 .048 c′ 0.018 0.032 .573 
     b 0.197 0.039 < .001 
  R2 = .05 
F(1, 76) = 4.049, p = .048 
 R2 = .25 
F(2, 75) = 12.4725, p < .001    
Note. IVIG = Intravenous Immunoglobulin; VAS = Visual Analog Scale; QOLSTIG = Quality of Life 
Stigma. 
 
 
     c = -0.018, p = .623 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Relationship between IVIG treatment experience and QOL stigma mediated by 
illness intrusiveness.  
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b = 0.197, p ˂ .001 
Direct effect, b = 0.018, p = .573 
Indirect effect, b = -0.036, 95% CI [-
.0841, -.0052] 
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QOL Cognition 
A mediation analysis was performed to assess the relationship of IVIG treatment 
experience on Neuro-QOL cognition through illness intrusiveness. The multiple 
regression was significant, R² = .164, F(2, 75) = 7.356, p = .0012 indicating IVIG 
treatment experience and illness intrusiveness explained about 16% of the variance in 
QOL cognition. Paths a and b respectively were, b = -0.184, t(76) = -2.012, p =.048; b = 
-0.196, t(76) = -3.834, p =.0003. The direct effect (cʹ) was not significant, b = -0.041, 
t(76) = -0.9903, p = .33. The total effect (path c) was not significant, b = -0.005, t(76) = -
.1211, p = .904.  
A percentile bootstrap confidence interval for the indirect effect (ab = 0.036) 
based on 10,000 bootstrap samples was entirely above zero 95% CI [0.0030, 0.0870] 
indicating mediation. I rejected the null hypothesis for the Neuro-QOL cognition scale. I 
performed a post hoc test with Gpower set at .005 probability error for Bonferroni 
correction which indicated a power of .62. The effect size k² = .10 with 95% CI [0.0123, 
0.2259] was medium. The mediation unstandardized coefficients are displayed in Table 
11 and the statistical indices in Figure 9. 
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Table  11 
Mediation Model Coefficients for IVIG Treatment Experience and QOL Cognition 
     Outcomes    
  M (Illness Intrusiveness)  Y (QOLCOG) 
Predictor Path  b SE p Path b SE p 
IVIG 
(VAS) 
a -0.184 .091 .048 c′ -0.041 0.042 .325 
     b -0.196 0.051  .0003 
  R2 = .05 
F(1, 76) = 4.049, p = .048 
 R2 = .164 
F(2, 75) = 7.3567, p = .0012    
Note. IVIG = Intravenous Immunoglobulin; VAS = Visual Analog Scale; QOLCOG = Quality of Life 
Cognition. 
 
 
 
 
    
 
 
 
 
 
 
 
      
 
 
 
 
 
 
Figure 9. Model of the relationship between IVIG treatment experience and QOL 
cognition mediated by illness intrusiveness. 
 
QOL Emotional and Behavioral Dyscontrol 
A mediation analysis was conducted estimating illness intrusiveness influence on 
the relationship between IVIG treatment experience and QOL emotional and behavioral 
dyscontrol (QOLEBD). The multiple regression was significant, R² = .197, F(2, 75) = 
9.212, p = .0003 indicating  the model explained 20% of the variance in QOLEBD. Path 
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b = -0.005, p = .904 
Direct effect, b = -0.041, p = .33 
Indirect effect, b = .036, 95% CI [.0030, 
.0870] 
 
a = -0.184, p = .048 b = -0.196, p = .0003 
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a was negative, b = -0.184, t(76) = -2.012, p = .048 and path b was positive and 
significant, b = 0.175, t(76) = 4.277, p = .0001.  The direct effect was negative and not 
significant, (cʹ), b = 0.021, t(76) = .615, p = .540. The total effect was not significant 
(path c), b = -0.012, t(76) = -.3213, p = .749. 
A bias-corrected bootstrap confidence interval for the indirect effect (ab = -0.032) 
based on 10,000 bootstrap samples did not include zero 95% CI [-0.0794, -0.0048] 
indicating mediation. I rejected the null hypothesis for Neuro-QOL emotional and 
behavioral dyscontrol. I performed a post hoc test with Gpower using .005 for alpha 
based on Bonferroni Correction which displayed a power of .77. The effect size k² = .11 
with 95% CI [0.019, 0.239] was medium. Table 12 presents the mediation indices and 
Figure 10 provides the statistical diagram of mediation. 
Table  12  
Mediation Model Coefficients for IVIG Treatment Experience and QOL Emotional and 
Behavioral Dyscontrol 
     Outcomes    
  M (Illness Intrusiveness)  Y (QOLEBD) 
Predictor Path  b SE p Path b SE p 
IVIG 
(VAS) 
a -0.184 0.091 .048 c′ 0.021 0.033 .5403 
     b 0.175 0.041  .0001 
  R2 = .05 
F(1, 76) = 4.049, p = .048 
 R2 = .197 
F(2, 75) = 9.2115, p = .0003    
Note. IVIG = Intravenous Immunoglobulin; VAS = Visual Analog Scale; QOLEBD = Quality of Life 
Emotional and Behavioral Dyscontrol. 
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Figure 10. Model of the relationship between IVIG treatment experience and QOL 
emotional and behavioral dyscontrol mediated by illness intrusiveness. 
 
QOL Lower Extremity Function 
A mediation analysis was conducted by estimating illness intrusiveness influence 
from IVIG treatment experience as well as QOL lower extremity function (QOLLEF) 
from both IVIG treatment experience and illness intrusiveness. The model was not 
significant at the .005 level, p < .005, R² = .11, F(2, 74) = 4.633, p = .01. Path a and b 
respectively were not significant, b = -0.176, t(75) = -1.902, p = .061; b = -0.153, t(75) = 
-2.626, p = .011. The direct effect was not significant (cʹ), b = 0.045, t(75) = .9414, p = 
.349 and the total effect (path c) was not significant, b = .072, t(75) = 1.483, p = .142. 
However, a bias-corrected bootstrap confidence interval based on 10,000 bootstrap 
samples did not include zero 95% CI [0.0029, 0.0745] indicating a small indirect effect 
(ab = .027). This supports current literature that it is possible to find an indirect effect 
IVIG Treatment  
Experience 
QOL Emotional and 
Behavioral Dyscontrol 
Illness Intrusiveness 
IVIG Treatment  
Experience 
QOL Emotional and 
Behavioral Dyscontrol 
a = -0.184, p = .048 b = 0.175, p = .0001 
Direct effect, b = 0.021, p = .5403 
Indirect effect, b = -.0321, 95% CI [-
.0794, -.0048] 
b = -0.012, p = .749 
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when a sound inferential test is employed even if path a or path b are not statistically 
significant since the indirect effect is the product of a and b and should not be based on 
hypothesis tests of a and b (Hayes, 2013). I rejected the null hypothesis for the Neuro- 
QOL lower extremity function. Effect size of k² = .06 with 95% CI [0.0081, 0.1683] was 
small. Table 13 provides the statistical indices and Figure 11 presents the statistical 
diagram of mediation. 
Table 13 
Mediation Model Coefficients for IVIG Treatment Experience and QOL Lower Extremity 
Function 
     Outcomes    
  M (Illness Intrusiveness)  Y (QOLLEF) 
Predictor Path  b SE p Path b SE p 
IVIG 
(VAS) 
a -0.176 0.093 .061 c′ 0.045 0.048 .350 
     b -0.153 0.058 .011 
  R2 = .046 
F(1, 75) = 3.62 p = .061 
 R2 = .111 
F(2, 74) = 4.634, p = .013    
Note. IVIG = intravenous immunoglobulin; VAS = Visual Analog Scale; QOLLEF = 
quality of life lower extremity function.  
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Figure 11. Model of relationship between IVIG treatment Experience and QOL lower 
extremity function mediated by illness intrusiveness. 
QOL Upper Extremity Function 
A mediation analysis was performed estimating illness intrusiveness influence 
mediated from IVIG treatment experience as well as QOL upper extremity function 
(QOLUEF) from both IVIG treatment experience and illness intrusiveness. There was no 
evidence that IVIG treatment experience influenced QOLUEF through illness 
intrusiveness. The model was not significant, R² = .027, F(2, 75) = 1.056, p = .353. Path a 
was negative b = -.184, t(76) = -2012, p = .048 and path b was not significant b = -0.015, 
t(2, 75) -0.4269, p = .671. The direct path was not significant (cʹ), b = 0.036, t(76) = 
1.258, p = .212 and the total effect was not significant , b = 0.039, t(76) = 1.397, p = .167. 
A 95% bias corrected confidence interval for the indirect effect (b = .0028) included zero 
IVIG Treatment 
Experience 
QOL Lower 
Extremity Function 
Illness Intrusiveness 
IVIG Treatment 
Experience 
QOL Lower 
Extremity 
Function 
b = .072, p = .142 
b = -0.176, p = .06 b = -0.153, p = .011 
Direct effect, b = .045, p = .35 
Indirect effect, b = .027, 95% CI 
[.0029, .0745] 
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(-.0097, .0218). I failed to reject the hypothesis for QOLUEF Upper Extremity Function. 
Figure 12 shows the relationship between IVIG treatment experience and QOLUEF not 
mediated by illness intrusiveness. Table 14 presents the statistical indices. 
Table  14 
Mediation Model Coefficients for IVIG Treatment Experience and QOL Upper Extremity 
Function 
     Outcomes    
  M (Illness Intrusiveness)  Y (QOLUEF) 
Predictor Path  b SE p Path b SE p 
IVIG 
(VAS) 
a -0.184 0.091 .048 c′ 0.036 0.029 .212 
     b -0.015 0.036 .671 
  R2 = .05 
F(1, 76) = 4.049, p = .048 
 R2 = .027 
F(2, 75) = 1.056, p = .353    
Note. IVIG = intravenous immunoglobulin; VAS = Visual Analog Scale; QOLUEF = 
quality of life upper extremity function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Model of the relationship between IVIG treatment experience and QOL upper 
extremity function not mediated by illness intrusiveness. 
 
IVIG Treatment  
Experience 
QOL Upper Extremity 
Function 
b = 0.039, p = .167 
Illness Intrusiveness 
IVIG Treatment 
Experience 
QOL Upper 
Extremity Function 
b = 0.184, p = .048 b = -0.015, p = .671 
Direct effect, b = 0.036, p = .212 
Indirect effect, b = .003, 95% CI [-.0097, 
.0218] 
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Research Question 3 
RQ3: Does personal control mediate the relationship between illness 
intrusiveness, and QOL (as measured by the 10 Neuro-QOL scales) among individuals 
with autoimmune disease who receive IVIG treatment? 
Mediation analysis was conducted to estimate if Personal Control (as measured by 
the MHLC – Form C) mediated the relationship between IVIG treatment experience 
(VAS) and QOL in neurological autoimmune patients. I performed mediation analysis 
using PROCESS Macro on all 10 of the Neuro-QOL subscales and employing the robust 
method of bootstrapping when conducting multiple regressions. According to the results 
with bias-corrected bootstrap of 10,000 samples there was no evidence of an indirect 
effect as all QOL variables effects included zero. In other words, there was no evidence 
that illness intrusiveness influenced QOL through personal control. Therefore, I failed to 
reject the null hypothesis that control influenced the relationship between illness 
intrusiveness and the Neuro-QOL variables. Table 13 displays the results of mediation 
analysis examining Hypotheses 3 estimating if personal control mediates the relationship 
between illness intrusiveness and QOL.  
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Table 15.  
Indirect effect of Illness Intrusiveness (X) on QOL (Y) through Personal Control (M) with 
No Mediation 
QOL Effect Boot SE 95% BC CI 
LL 
95% BC CI 
UL 
QOLSSRA .0011 .0007 -.0068 .0237 
QOLFATIG .0003 .0043 -.0064 .0124 
QOLDEPR       -.0015 .0070 -.0234 .0071 
QOLPAWB .0023 .0088 -.0093 .0320 
QOLSLP       -.0008 .0052 -.0176 .0063 
QOLCOG .0019 .0092 -.0087 .0361 
QOLEBD .0002 .0052 -.0085 .0126 
QOLSTIG .0006 .0056 -.0060 .0191 
QOLLEF .0019 .0081 -.0070 .0290 
QOLUEF .0004 .0036 -.0043 .0119 
Note: BC CI LL = bias-corrected confidence interval lower limit; BC CI UL = bias-
corrected confidence interval upper limit;  QOLSSRA = quality of life satisfaction with 
social roles and activities; QOLFATIG = quality of life fatigue; QOLDEPR = quality of 
life depression; QOLPAWB = quality of life positive affect and well-being; QOLSLP = 
quality of life sleep; QOLCOG = quality of life cognition; QOLEBD = quality of life 
emotional and behavioral dyscontrol; QOLSTIG = quality of life stigma; QOLLEF = 
quality of life lower extremity function; QOLUEF = quality of life upper extremity 
function. 
 
Summary 
The purpose of this chapter was to test three hypotheses regarding the relationship 
of IVIG treatment experience and QOL in neurological autoimmune patients. 
Specifically, the study investigated if IVIG treatment experience predicted QOL, if IVIG 
treatment experience influenced QOL through illness intrusiveness and if illness 
intrusiveness influenced QOL through personal control. 
Research Question 1 revealed mixed results. One of the 10 Neuro-QOL subscales 
showed significant correlation; QOL positive affect and well-being. Therefore, the first 
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null hypothesis was rejected for that one QOL scale. However, the other nine subscales 
did not reveal correlation at the error probability of .005 so I failed to reject the first 
hypothesis for QOL satisfaction with social roles and activities, QOL depression, QOL 
fatigue, QOL sleep, QOL stigma, QOL cognition, QOL emotional and behavioral 
dyscontrol, QOL lower extremity function, and QOL upper extremity function. However, 
as was previously acknowledged since current literature regarding mediation no longer 
requires the simple association between X and Y in order to test for mediation (Hayes, 
2013; Rucker et al., 2011) I proceeded with Research Question 2 for all ten of the Neuro-
QOL variables. 
Research Question 2 was answered by performing 10 mediation analysis 
estimating illness intrusiveness influence from IVIG treatment experience as well as 
QOL from both IVIG treatment experience and illness intrusiveness. A significant 
indirect effect was found for nine of the QOL subscales supported by the robust test of 
bias-corrected or percentage bootstrapping with 10,000 samples. Therefore, I was able to 
reject the null hypothesis for Research Question 2 in nine of the Neuro-QOL subscales. 
The only subscale that did not show an indirect effect or mediation was QOL upper 
extremity function. I failed to reject the null hypothesis for QOL upper extremity function 
for Research Question 2.  
Research Question 3 was answered by a mediation analysis using PROCESS in 
order to determine if personal control influenced the relationship of illness intrusiveness 
on Neuro-QOL. All 10 QOL variables indicated no significant results, there was no 
indirect effect of illness intrusiveness on QOL through personal control. Therefore, I 
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failed to reject the null hypothesis for Research Question 3. The results of the study are 
discussed in more detail in Chapter 5. 
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 Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The purpose of this research was to examine the impact of IVIG treatment 
experience on the QOL of neurological autoimmune patients. It was hypothesized that 
IVIG treatment experience may intrude on the activities and lifestyle of patients through 
the construct illness intrusiveness which may affect QOL (Devins, 2010; Poochikian-
Sarkissian et al, 2008a). The study specifically examined whether illness intrusiveness 
mediated the relationship between IVIG treatment experience and QOL.  
Patients may vary as to how they react to the IVIG treatment experience or 
whether they consider the experience as intrusive which in turn may impact QOL. The 
illness intrusiveness theoretical framework also suggests that personal control may be 
limited by illness intrusiveness in that the individual is not able to control negative 
outcomes or influence positive ones (Devins, 2010). Considering this possibility, the 
study also tested whether personal control was a mediator between illness intrusiveness 
and Neuro-QOL. Although research has supported the effectiveness of IVIG treatment 
with autoimmune neurological disorders, there is no research relating to how the IVIG 
treatment experience may potentially influence illness intrusiveness, which in turn might 
affect QOL and only limited research regarding the relationship of IVIG and QOL with 
neurological autoimmune patients (Padua et al., 2005).  
It is important for the medical treatment teams to understand how the experience 
of receiving this particular treatment might be affecting the patient’s QOL so that 
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accommodations or treatment plans might be managed to support better patient care 
(Padua et al., 2005). Although medical staff may be aware of the fact that IVIG treatment 
may mean lengthy hours, strain on financial resources, complex treatment schedules, etc., 
they may not be knowledgeable as to how these ramifications from IVIG treatment affect 
the patient emotionally. The purpose of this study was to contribute to literature regarding 
IVIG treatment experience and to elucidate understanding of the consequences of the 
IVIG treatment experience on quality of life for CIDP, MS, MMN, and MG patients. This 
chapter contains interpretation of the findings of the data analysis in Chapter 4.  
Interpretation of the Results 
Prior to data analysis, I performed descriptive analysis. The data consisted of 79 
returned questionnaires from neurological autoimmune patients receiving IVIG at PNA, 
an infusion center in Phoenix, AZ. The sample consisted of 25 (31.6%) males and 54 
(68.4%) females. The sample included 30 MS patients, 25 CIDP patients, 13 MG 
patients, and 11 MMN patients.  
Hypothesis 1: IVIG Treatment Experience as a Predictor of Quality of Life 
IVIG treatment experience significantly predicted QOL in patients with MS, 
MMN, MG, and CIDP in the Neuro-QOL scale positive affect and well-being subscale. 
Research indicates people experiencing the four diseases represented in this study have a 
lower QOL in comparison to healthy individuals (Benito-Leόn et al., 2003; Cocito et al., 
2006; Mitchell et al., 2005). It was a surprise that the IVIG treatment experience was not 
significantly correlated with more of the Neuro-QOL subscales. Although there has been 
no research examining the relationship of IVIG treatment experience and QOL, the 
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correlation of IVIG treatment experience and outcome variables seemed expected when 
considering that QOL seems to be impacted by these chronic diseases and treatment 
according to research (Avis et al., 2005; Richardson et al., 2008; Shawaryn et al., 2002). 
It was interesting to note that three of the outcome variables dropped from significance 
once we incorporated the Bonferroni Correction. 
There was positive significant correlation (r = .339; p = .002) between IVIG 
treatment experience and QOL positive affect and well-being. It is possible that the 
patients receiving treatment view their chronic disease differently due to treatment and 
have an improved appreciation for life such as was found in one study where patients 
viewed their life as becoming more meaningful as a result of their chronic illness (de 
Ridder et al., 2008). Perhaps some of the patients viewed the IVIG treatment as a means 
to physical improvement which also makes their overall well-being enhanced. Perception 
of their well-being influences how the patient perceives their own QOL (Megari, 2013). 
Positive affect and well-being is part of the psychological domain of QOL and the 
positive correlation between IVIG treatment experience and this QOL scale indicates that 
as the patient views the experience positively their perception of their own positive affect 
and well-being improves. It may be that neurological autoimmune patients suffering from 
a chronic disease perceive the IVIG experience not only improves their physical abilities 
and function but improves their attitude toward life. 
Three other outcome variables were correlated with the IVIG experience although 
not at the significant level. This was unexpected as previous literature would suggest 
there might have been a higher correlation. For example, fatigue is a common thread in 
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chronic neurological disorders which can ultimately affect QOL. The negative correlation 
between IVIG treatment experience (VAS) and fatigue in this study (b = -.294; p < .009) 
supports previous research that showed fatigue has a negative impact on people with 
neurological disease (Kobelt et al., 2006) and was a main problem interfering with QOL 
and daily activities (Boukhris et al., 2005). In MG, fatigue is easily exacerbated 
(Kulaksizoglu, 2007), is the symptom most often reported in MS (Dayapoglu & Tan, 
2011), can be a major issue in CIDP (Van den Bergh et al., 2010), and correlates with 
higher levels of disability (Pittion-Vouyovitch et al., 2006). Considering the different 
aspects of IVIG treatment including rearranging life schedules, lengthy administration 
hours, and possible side effects as well as potential for improved physical symptoms, it 
was reasonable to postulate that IVIG treatment might be viewed as a factor in overall 
QOL fatigue. Patients may become fatigued by the long range (often for life) 
administration of IVIG treatment (Jolles et al., 2005). 
Similarly, depression has been an observable symptom in these chronic 
autoimmune diseases (Amato et al., 2001; Dayapoglu, 2011). The negative correlation 
although not significant between IVIG treatment experience and QOL depression 
supported similar research which found depression high in autoimmune disease (Chen et 
al., 2009) along with a study which found depression correlated to lower QOL (Janardhan 
& Bakshi, 2002). As IVIG patients viewed the totality of their experience with treatment 
as positive, both the depression and fatigue decreased. However, both of these variables 
did not meet the Bonferroni requirements (p < .005) as both had the same correlations (r 
= -.294; p = .009). Although the correlations did not reach significant level, the similar 
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results might indicate there may be a correlation between fatigue and depression in those 
patients receiving IVIG which will be addressed later under other noteworthy findings. 
Additionally, although not significant (r = .320; p = .005), there was a positive 
correlation between IVIG treatment experience and QOL satisfaction with social roles 
and activities. Previous research showed fewer impairment issues from disease relates to 
more leisure activity and participation allowing the patient satisfaction in their social 
roles (Vanner et al., 2008). Actually, illness intrusiveness may be considered an 
impairment issue. If the IVIG treatment itself becomes intrusive due to complicated 
schedules, disrupted employment, or side effects, then patients may become dissatisfied 
with their social role or inability to participate in activities. Additionally, if the patient 
deems the whole IVIG experience as beneficial, they may view themselves more capable 
and be more apt to participate in activities within their community or family such as 
service clubs, family games, or even holiday gatherings. They may even be encouraged to 
venture forth and attempt to participate in a leisure activity such as swimming, bowling, 
or attending a concert. They may also feel more content and satisfied with the current 
state of their social roles. The other six QOL scales showed no correlation with IVIG 
treatment experience which was a surprise. I would have expected there to be a 
correlation between upper and lower extremity function as some patients experience 
more mobility after an infusion (PNA, 2015). 
Hypothesis 2: Illness Intrusiveness as a Mediator 
The second research question examined whether the illness intrusiveness 
construct mediates the IVIG treatment experience and QOL as measured by 10 subscales 
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of the Neuro-QOL. It is important to note that this is the first research study to examine 
the possibility of the relationship between IVIG treatment experience and QOL mediated 
by illness intrusiveness. As was previously noted, illness intrusiveness has been defined 
as the degree disruptions of disease or treatment interrupt patient interests and meaningful 
activities (Devins, 2010). How a patient reacts to potential intrusion of treatment may 
make a difference in aspects of their QOL. Since illness intrusiveness correlated with 
nine of the QOL of life variables, it was meaningful to look further and examine whether 
illness intrusiveness acted as a mediating variable between IVIG treatment experience 
and QOL. By asking Research Question 2, I examined if the predictor IVIG treatment 
experience indirectly influenced the dependent variables QOL through the mediator, 
illness intrusiveness.  
IVIG treatment experience indirectly influenced QOL through illness 
intrusiveness in nine of the 10 Neuro-QOL subscales tested in the current study. That is, 
illness intrusiveness mediated the relationship between IVIG treatment experience and 
QOL fatigue, QOL depression, QOL satisfaction with social roles and activities, QOL 
positive affect and well-being, QOL cognition, QOL stigma, QOL sleep, QOL emotional 
and behavioral dyscontrol, and QOL lower extremity function supporting the illness 
intrusiveness theory which suggests the construct does not directly affect QOL but acts as 
a mediator between the treatment and the QOL due to the factors such as disrupted 
activities, side effects, and complex schedules (Devins, 2010). These findings are 
important as they provide a possible explanation that illness intrusiveness is a construct 
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influencing QOL in this population of patients. How a patient interprets or perceives the 
level of intrusiveness of IVIG treatment influences the outcome QOL  
Illness intrusiveness significantly predicted nine of the 10 QOL subscales which 
was consistent with previous research which found illness intrusiveness correlated with 
many indicators of QOL (Devins, 2010). This pattern supported Devins’s (1993) theory 
that disease treatment may affect illness intrusiveness which in turn affects QOL. 
Moreover, since an indirect effect was found in nine of the mediation analyses, the study 
supports previous research which concluded illness intrusiveness is a mediator in various 
chronic diseases (Dancey et al., 2002; Devins et al., 1990; Devins et al., 1997; Lebel, 
Beattie, Arès, & Bielajew, 2013; Poochikian-Sarkissian et al., 2008a).  
Important for these particular patients is how they evaluate the IVIG experience 
as an intrusive factor in their QOL determines the very value of the life experience. This 
may well offer an explanation as to why some patients accept the complications which 
may occur with the process of IVIG and others may become highly affected. For 
example, Bloom et al. (1998), in examining 308 breast cancer patients, found that disease 
treatment and QOL was mediated by illness intrusiveness, and Dancey et al. (2002) found 
illness intrusiveness was a significant mediator between symptom severity and QOL in 
irritable bowel syndrome sufferers supporting Devins’s (1994) theory that illness 
intrusiveness is a mediating construct. Another important similarity in the current study 
and previous research suggested by the results of mediation analysis is that increased 
illness intrusiveness correlates significantly with decreased QOL as well as indicating 
illness intrusiveness may be an important contributor to the psychosocial impact of 
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disease treatment supporting previous research studies (Dancey et al., 2002; Poochikian-
Sarkissian et al., 2008a; Shawaryn et al., 2002).  
Other research has demonstrated illness intrusiveness correlated with such QOL 
factors as fatigue and depression (Goudsmit et al., 2009). Additionally, in the Shawaryn 
et al. (2002) study, illness intrusiveness mediated disease severity and depression, upper 
extremity function, memory, and fatigue. Similarly, in the current study, illness 
intrusiveness mediated the relationship between IVIG treatment experience and QOL 
fatigue, QOL depression, and QOL cognition. The positive relationship showed more 
illness intrusiveness led to more fatigue and depression in this study. However, the 
negative relationship between illness intrusiveness and cognition would suggest cognition 
might be poorer when more illness intrusiveness was present. This finding supported the 
previous literature as well as the Illness Intrusiveness theory.  
In order to understand the impact of IVIG treatment experience on QOL it is 
necessary to depict the degree that a patient perceives the treatment as helpful or on the 
other hand disruptive. Although this study resulted in nine quantified indirect effects of 
IVIG treatment experience on QOL through illness intrusiveness, some of them seem to 
reflect a larger effect size perhaps indicating more effect on QOL. Looking closer at the 
individual Neuro-QOL subscales there are some interesting observations. For example, 
46% or almost half of the variance in the QOL satisfaction with social roles and activities 
variable was explained by both IVIG treatment experience and illness intrusiveness. 
However, only a small portion (R² = .05) of the total variance is accounted for by the 
IVIG treatment experience. The larger portion of the total variance is carried by illness 
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intrusiveness. This would support the concept that fatigue, complex schedules, side 
effects, and other factors involved in the construct of illness intrusiveness and how it 
relates to IVIG treatment experience may decrease the patient’s ability or desire to 
participate in various social activities. The relationship is negative meaning that as illness 
intrusiveness increases QOL satisfaction with social roles and activities decreases. In 
essence, one might speculate that if the intrusiveness of the IVIG treatment experience 
could be diminished a patient might enjoy improved social relationships or activities.  
The mediation model explained 33% of the variance in QOL depression and 39% 
of the variance in fatigue. Although that variance allows for other possible unidentified 
mediators or factors in the dependent variables QOL depression and QOL fatigue the 
variance explained in this study was considerable. However, once again, illness 
intrusiveness explains most of the variance in these mediation models as the IVIG 
treatment experience only accounts for about 5% of the total variance. Previously, fatigue 
has been found to negatively affect QOL in neurological disorders (Kobelt et al., 2006). It 
is clear from the results of the positive effect of illness intrusiveness on depression and 
fatigue that as the patient considered the treatment experience to be more disruptive or 
intrusive depression and fatigue increased. Similar results were found in earlier research 
when more fatigue was expressed by MS patients when higher levels of illness 
intrusiveness were present (Shawaryn et al, 2002). Fatigue is a common feature in these 
four autoimmune diseases but the pathogenesis is unclear (Merkies & Faber, 2012) and it 
sometimes prevents individuals from social and family activities. The implication that 
QOL can be either positively or negatively affected by IVIG treatment and illness 
130 
 
intrusiveness is clear from the results in the current study. The study implies illness 
intrusiveness may add to the impact of QOL variables in the neurological autoimmune 
patient. It may be possible for example that a patient might have side effects of IVIG 
treatment, or work interruptions created due to the IVIG schedule which might then cause 
more fatigue or depression. As mentioned previously, IVIG is an expensive therapy 
which may or may not be covered by insurance. This complication alone may be a factor 
in increased depression or fatigue experienced by the patient. How a patient interprets 
each intrusion may influence their QOL. 
Looking closer at the mediation analysis of IVIG treatment experience on QOL 
positive affect and well-being once again the total variance of 27% was mostly accounted 
for by illness intrusiveness. There was a negative relationship which was in the expected 
direction in that when illness intrusiveness increased a patient’s positive affect and 
feelings of well-being decreased. Interestingly, the mediation analyses between IVIG 
treatment experience and QOL sleep showed a variance of 35% with most again being 
accounted for by illness intrusiveness. The negative relationship meant that as IIRS 
increased the sleep scores decreased which meant more sleep disturbance and interrupted 
sleep patterns. Again, this would be in the expected direction and supported previous 
research which showed poorer sleep quality with neurological disability patients (Happe, 
2003; Lobentanz et al., 2004; Stepansky et al., 1997)  
The fact that QOL lower extremity function showed mediation and QOL upper 
extremity function did not show mediation was interesting but could reflect that lower 
extremity mobility is more affected by the disruptive factors of treatment. It may simply 
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be that patients view their ability to walk and move as the most important factor in 
extremity function. There is another interesting point regarding the mediation with QOL 
lower extremity function. Although the direct effect and the total effect were not 
significant a bias-corrected confidence interval signified a small indirect effect supporting 
current literature which posited an indirect effect may be present even when paths a and b 
are not significant (Hayes, 2013). It would be reasonable to conclude IVIG treatment 
experience does influence QOL lower extremity function through illness intrusiveness to 
some degree.  
It is interesting to note that eight of the mediations in this study showed a medium 
effect size with only QOL lower extremity function showing a small effect size. This is 
important to consider as this is the first study investigating the illness intrusiveness theory 
with neurological autoimmune patients receiving IVIG treatment. It is also the first study 
investigating illness intrusiveness and MMN, MG, and CIDP. However, considering the 
indirect effect sizes (k²) were medium there is also room to consider other potential 
mediating variables which might influence that relationship. One of those potential 
mediators which might be tested would be coping. 
Hypothesis 3: Personal control as a mediator (Null not rejected) 
There was no significant indirect effect of personal control on the relationship 
between illness intrusiveness and Neuro-QOL in each mediation analyses with the 10 
QOL variables. There was also no correlation between illness intrusiveness and personal 
control. This was a surprise as one would expect personal control to be associated with 
QOL since previous research shows low levels of personal control were associated with 
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high levels of illness intrusiveness (Poochikian-Sarkissian et al., 2008a). On the other 
hand, one other study examining the relationship of diabetic complications and 
depressive symptomology mediated by illness intrusiveness found that a better fitting 
model excluded personal control (Talbot et al., 1999). The illness intrusiveness theory 
implies illness intrusiveness negatively influences psychological well-being by reducing 
personal control and the individual’s ability to achieve positive outcomes (Devins, 2010). 
The results of this study did not support personal control mediating the relationship 
between IVIG treatment experience and QOL. This could be that patients surveyed do not 
view themselves as having a lack of control over their IVIG treatment experience. It may 
also imply patients do not consider personal control has any influence on the relationship 
between how intrusive they consider IVIG treatment is to their QOL. 
Other Noteworthy Findings 
In addition to the one QOL subscales that correlated with IVIG treatment 
experience as measured by VAS there were some other interesting correlations between 
some of the other Neuro-QOL subscales that are worth noting. These additional findings 
may be important in helping medical staff understand some of the psychological factors 
which may be prevalent in IVIG patients and assisting them in determining treatment 
direction. For example, the moderate negative correlation between QOL depression and 
QOL positive affect and well-being supports previous research which found reduced 
positive affect is distinct to depression (Forbes & Dahl, 2005). Another importance of 
such a correlation in this study is that depression has been viewed for some time as a 
predictor of increased health risks (Cohen & Pressman, 2006). Higher levels of positive 
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affect may increase social interaction which may in turn help the patient experience 
needed social support during the IVIG treatment experience. It is also possible that 
positive affect may result in fewer disease symptoms being reported by the patient 
(Cohen et al., 2003). Thus, such a correlation could be of significance to medical staff so 
they will be aware of potential vulnerability to risks for some patients. Similarly, the 
moderate negative correlation between QOL depression and QOL satisfaction with social 
roles and activities supported previous research which found an inverse relationship 
between social activity and depression (Holtfreter, Reisig, & Turanovic, 2015). 
The moderate positive correlation between QOL fatigue and QOL depression 
supported previous research which found that more fatigue correlated with increased 
depression (Pittion-Vouyovitch et al., 2006). The negative moderate correlation between 
QOL fatigue and QOL cognition reinforced findings that attention, memory, and 
cognition may be affected by neurological disease but may also mean consideration 
might be warranted to consider the effect fatigue might have on aspects of cognition. 
Fatigue was found to be a significant predictor of self-reported cognitive concerns among 
MS patients in a recent study using the same measurement Neuro-QOL subscale as in this 
study (Beier, Amtmann, & Ehde, 2015). The challenges of fatigue and cognition may 
indeed make daily life more difficult. Moreover, the negative correlation between QOL 
depression and QOL cognition supported research that found depression and fatigue 
influence subjective complaints about cognition in MS patients (Kinsinger, Lattie, & 
Mohr, 2010) along with another study that found depression was associated with 
subjective cognitive impairment (Julian, Merluzzi, & Mohr, 2007). The Kinsinger et al. 
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(2010) study administered a 16 week telephone treatment program for depression and 
found post treatment results indicate subjective cognition complaints may be decreased 
through treatment. Likewise, the current research may provide IVIG nurses information 
regarding the importance of the relationship between depression and cognitive complaints 
which may encourage them in identifying patients with these symptoms. 
Mobility and physical functioning are very important to neurological patients as 
sometimes problems are experienced in these realms. The moderate positive correlation 
between QOL lower extremity function and QOL satisfaction with social roles and 
activities supported previous research which found lower limb function was rated most 
important affecting QOL negatively in patients with chronic neurological disease (Heesen 
et al. 2008; Pike et al., 2012). Problems with sleep quality have also been linked with 
neurological disability in MS patients and MG patients (Lobentanz et al., 2004; 
Stepansky et al., 1997). The correlations in the current research study support those 
findings as QOL sleep showed significant strong correlation with QOL fatigue meaning 
that as the patient experienced more fatigue quality of sleep decreased. QOL fatigue 
displayed moderate negative correlation with QOL satisfaction with social roles and 
activities. Similarly, other research reported fatigue as a major problem interfering with 
patients participating in family and professional activities (Boukhris et al., 2005). 
Inflammation is a characteristic of most autoimmune diseases which research 
suggests can lead to depression in those patients who are susceptible (Dantzer et al., 
2008). In the current study, QOL depression was moderately positively correlated with 
QOL sleep and QOL stigma. This positive relationship supported previous research 
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which suggests individuals with neuromuscular diseases experience strong feelings of 
stigma (van der Beek et al., 2013). 
The results also supported research by Feinstein and Feinstein (2001) who found 
that QOL may be impacted by symptoms of emotional dyscontrol. The variable QOL 
emotional and behavioral dyscontrol showed significant correlation with seven of the 10 
QOL variables in the current study. While it is true only one of the correlations in the 
current study showed significance between IVIG treatment experience and QOL, it is 
important to recognize that other QOL correlations were apparent which support previous 
research. Finally, it is important to mention illness intrusiveness (the mediator in the 
current study) significantly correlated with all QOL subscales with the exception of QOL 
upper extremity function supporting previous research which found illness intrusiveness 
correlated with QOL in a number of conditions (Devins et al., 2013; Mucsi et al., 2004; 
Shawaryn et al., 2002; Snyder et al., 2013). However, Illness intrusiveness also did not 
correlate with personal control (HCS).  
Limitations 
The current study was composed of returned surveys from 79 neurological 
autoimmune patients receiving IVIG treatment. One limitation would be that all patients 
came from the same IVIG infusion center so while generalizing the results to similar 
infusion centers may be possible making a national population generalization of these 
diseases may not possible. However, all four diagnoses in the study were representative 
of autoimmune diseases receiving IVIG, and the staff of this facility indicated that it is 
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fairly typical of most treatment centers of this kind. Another limitation is that patients 
could not be randomly selected but volunteered to participate in the study.  
Question #13 of the IIRS was inadvertently omitted from the survey given to 
participants. The question asked how much the patient’s illness interfered with their civic 
involvement. Therefore, the IIRS instrument did not match perfectly the original 
instrument and could potentially be a threat to the validity of findings. Questions similar 
to this one are part of the QOL satisfaction with social roles and activities. This Neuro-
QOL subscale had eight questions for the patient to evaluate their ability and satisfaction 
with social roles and life in the community. Exclusion of a question of similar content in 
the IIRS could have potentially impacted the correlation coefficient between the IIRS and 
the satisfaction with social roles and activities subscale of the Neuro-QOL. 
Implications 
A premise of mediation analysis is that relevant underlying aspects of behavior 
might be identified so that interventions might be developed based on those variables 
identified (MacKinnon & Fairchild, 2009). IVIG is the common treatment for the four 
neurological diseases in the current study but that treatment comes with possible 
psychological, social, or emotional elements. Since indirect effects were found in this 
study results may be helpful in identifying in what areas IVIG patients deem IVIG 
treatment experience interferes with their lifestyle. This information could potentially 
assist medical staff or infusion centers in evaluating patient risks, needs, and help them 
create new effective services. For example, a patient might view the complicated 
scheduling of IVIG therapy as interfering (illness intrusiveness) with his ability to hold a 
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full time employment position and therefore may experience depression or lost sleep over 
the dilemma. If the medical staff involved in his/her treatment is aware of the situation 
there might be a plan devised to rearrange a schedule which would help to bring positive 
results for the patient and eventually reduce depression or increase the patient’s ability to 
sleep. Moreover, it is possible that IVIG treatment is affecting other areas of the patient’s 
life such as family relationships, freedom to travel, or the pursuit of goals and the results 
of this study may help the treatment team be more aware of the influence of IVIG 
treatment on a patient’s QOL so they might ascertain what areas of the patient’s life are 
being affected by the treatment and provide a plan or counseling in this regard.  
Some patients may be able to deal and cope with the additional challenges of a 
long term treatment which may need to be completed in a hospital or infusion center and 
others may have more trouble adjusting to ongoing treatment. Identifying the areas where 
some patients are most challenged in the IVIG treatment process may make designing 
individual care plans more effective. One of the goals of this study was to provide IVIG 
nurses, patients, and treatment teams a richer understanding of the psychological factors 
in the IVIG treatment experience and in what areas those factors are influencing overall 
QOL. The findings of this study could potentially provide some answers for IVIG 
patients and staff since this was the first research study involving IVIG treatment 
experience and illness intrusiveness with this population. 
Implications for Social Change 
It is possible the results of the current study could be useful for positive social 
change as policy makers now will have some documentation and literature as to the effect 
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IVIG treatment experience has on the lives of patients. Certainly, the study can be shared 
with such pharmaceutical companies as Biofusion, which provides IVIG to many nurses 
across the country who then provide at home IVIG treatment. Understanding some of the 
psychological or emotional responses which might occur as a result of the IVIG treatment 
experience could assist infusion nurses in accommodating or modifying situations which 
might add to patient stress. It may also be helpful in guiding nurses or members of the 
treatment team as to appropriate counseling needed by the patient. When human and 
social conditions are improved, positive social change occurs in society (Walden 
University, 2013, p. 13).  
This study impacts positive social change by potentially improving human and 
social conditions in three major ways: (a) the research study clarifies illness intrusiveness 
mediates the relationship of IVIG treatment experience on QOL, thus contributing to the 
understanding of the effects of this therapy on QOL in MMN, MG, MS, and CIDP 
patients;  (b) the results of this study will be distributed to the staff at PNA, thereby 
adding to the medical staff’s knowledge base in order to assist them in improving their 
patient’s human and social condition; and (c) results will be made available to any 
interested nurses or stakeholders as they may find the information useful as they plan 
interventions for their IVIG patients treatment experience.  
Recommendations 
The current study was the first to examine the IVIG treatment experience and 
QOL. It was also the first study to investigate if illness intrusiveness was a mediator of 
the IVIG treatment experience and QOL. My first recommendation would be that the 
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study be replicated with another infusion center or in a hospital setting with IVIG 
patients. Perhaps a different geographical area might be an interesting perspective and 
provide further research support. While it appeared obvious from the study that IVIG 
treatment experience has an effect on the physical, psychological, and social aspects of 
QOL further research in a different facility might add to the current conclusions. Another 
idea might be to explore whether patients view lower extremity function as more 
important than upper extremity function since mediation occurred in lower extremity 
function but not in upper extremity function. 
Although the majority of the effect sizes of mediation were medium there would 
appear to be other potential mediators of the IVIG treatment experience and QOL. One 
possible mediator of the IVIG treatment experience and QOL might be coping ability as 
this may in turn affect the levels of the patient’s perceived intrusiveness of the treatment 
experience (i.e., complex schedules, side effects, etc.). In addition, it would seem 
interesting and worthy to explore coping as a possible mediator of illness intrusiveness 
and QOL since personal control was not a mediator in this patient population. It is 
reasonable to surmise coping ability is often required for IVIG patients to adjust to the 
many life changes which occur with long term medical treatment. This study used a 
single question visual analogue scale to measure the IVIG treatment experience. A 
different researcher may want to create a different scale with more questions. Finally, it 
might we worthy to explore individual emotions and psychological responses of IVIG 
patients through a qualitative approach interviewing patients who have been receiving 
this therapy for different period of times. 
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Conclusion 
I began this research study for several reasons. Since being diagnosed with the 
neurological autoimmune disease, CIDP, 15 years ago, I was motivated to understand 
how IVIG treatment affects the QOL in patients with similar diagnoses receiving this 
treatment. It was clear to me as I received IVIG in many settings (infusion center, 
hospital, and at home) that my reaction to the treatment was not necessarily the same as 
many other patients. While completely aware of the ramifications which can occur from 
treatment such as scheduling problems, family disruptions, side effects, financial 
challenges, etc. I was also observing some patients seemed to deal with the challenges 
better than others. Thus, the desire arose to examine the relationship of IVIG treatment 
experience on QOL.  
Three main hypotheses were examined in this study: (a) whether IVIG treatment 
experience predicted QOL in neurological autoimmune patients, (b) if the IVIG treatment 
experience indirectly affected QOL through illness intrusiveness, and (c) if personal 
control mediated the relationship between illness intrusiveness and QOL. According to 
the results, illness intrusiveness does mediate IVIG treatment experience and QOL in 
nine of the outcome variables demonstrating that illness intrusiveness is an important 
contributor to this relationship. The results of this study provide new and important 
information regarding the IVIG treatment experience and QOL. It is hoped the results 
will help nurses and medical personnel to understand the psychological effect of 
treatment on patient’s QOL so that new or improved treatment plans may be developed 
which may serve to decrease some of the negative effects of the IVIG experience on 
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QOL. It is also hoped that this study will encourage future research into the effects of 
IVIG treatment experience on neurological autoimmune patients. 
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Appendix A: Project Questionnaire 
I. Please indicate your gender by placing an x on the line: 
 Male ____________ Female _____________ 
 
2. Age, please circle the appropriate group for your age: 
 
 21-30  30-40  40-50  50-60  60-70  70-80 
 
3. Employment Status: Please circle one. 
 
 Employed or Self-employed   Unemployed 
 
4.. Please circle your medical diagnosis: 
 
 Multiple Sclerosis (MS) 
 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 
 
 Myasthenia Gravis (MG) 
 
 Multifocal Motor Neuropathy (MMN) 
 
5. How long have you had this diagnosis (months and years) __________________ 
 
6. How often do you receive IVIG treatment? 
 
 a. Every 8 weeks or a longer time between treatments 
 
 b. Every 6-7 weeks. 
 
 c. Every 4-5 weeks 
 
 d. Every 3 weeks 
 
 e. Every 2 weeks or more often 
 
7. How long does the administration of your IVIG infusion last?  
 
 a. 1 hour 
 
 b. 2 hours 
 
 c. 3  hours 
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 d. 4 hours 
 
 e. 5 or more hours 
 
8. I receive pre-medication before receiving IVIG treatment. Please circle your answer. 
 
 Yes    No 
 
9. After IVIG treatment I experience side effects other than fatigue 
 
 a. Never 
 
 b. Sometimes 
 
 c. Most of the time 
 
 d. Always 
 
10. Think about your experience with IVIG treatment which includes symptom relief, 
side effects, financial cost, changes from usual activities, improved health, adjusting 
schedules or family events, improved mobility and place a mark on the line where you 
think it best represents what your experience has been overall. 
Anchors: 
As bad as it can be ..........................................................................................As good as it 
can be 
 
 
